

REFINITIV

DELTA REPORT

10-Q

XRAY - DENTSPLY SIRONA INC.

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1495
CHANGES	160
DELETIONS	775
ADDITIONS	560

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended **September 30, 2023** **March 31, 2024**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the transition period from to

Commission File Number 0-16211

DENTSPLY SIRONA Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

39-1434669

(I.R.S. Employer
Identification No.)

13320 Ballantyne Corporate Place, Charlotte, North Carolina

(Address of principal executive offices)

28277-3607

(Zip Code)

(844) 848-0137

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value \$.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer x

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: At **October 30, 2023** **April 19, 2024**, DENTSPLY SIRONA Inc. had **211,860,391** **207,630,556** shares of common stock outstanding.

DENTSPLY SIRONA Inc.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	Page
Item 1	Financial Statements (unaudited)	4
	Consolidated Statements of Operations	4
	Consolidated Statements of Comprehensive Income (Loss) Comprehensive Loss	5
	Consolidated Balance Sheets	6
	Consolidated Statements of Changes in Equity	7
	Consolidated Statements of Cash Flows	8
	Notes to Unaudited Interim Consolidated Financial Statements	9
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	34
Item 3	Quantitative and Qualitative Disclosures About Market Risk	47
Item 4	Controls and Procedures	47
PART II	OTHER INFORMATION	
Item 1	Legal Proceedings	48
Item 1A	Risk Factors	48
Item 2	Unregistered Sales of Securities and Use of Proceeds	48
Item 6	Exhibits	49
Signatures		50

General

Unless otherwise stated herein or the context otherwise indicates, reference throughout this Form 10-Q to "Dentsply Sirona," or the "Company," "we," "us" or "our" refers to financial information and transactions of DENTSPLY SIRONA Inc., together with its subsidiaries on a consolidated basis.

Forward-Looking Statements and Associated Risks

All statements in this Form 10-Q that do not directly and exclusively relate to historical facts constitute "forward-looking statements" and include statements related to our ability to successfully remediate the material weaknesses in our internal control over financial reporting disclosed in this Form 10-Q in the manner currently anticipated. These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as amended December 31, 2023 (the "2022" "2023 Form 10-K"), and other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

Disclosure Regarding Trademarks

This report includes trademarks, **tradenames** **trade names** and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and **tradenames** **trade names** sometimes appear without any "TM" or "®" symbol. Failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and **tradenames**, **trade names**.

PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts)

(unaudited)

		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended March 31,	
		2024		2024		2024	
		Three Months Ended September 30,		Nine Months Ended September 30,			
Net sales		2023		2022		2023	
Net sales							
Net sales	Net sales	\$	947	\$	947	\$	2,953
Cost of products sold	Cost of products sold		452		439		1,389
Cost of products sold							
Cost of products sold							
Gross profit	Gross profit		495		508		1,564
Gross profit							
Gross profit							
Selling, general, and administrative expenses							
Selling, general, and administrative expenses							
Selling, general, and administrative expenses	Selling, general, and administrative expenses		372		401		1,204
Research and development expenses	Research and development expenses		46		41		141
Goodwill and intangible asset impairments			307		1,281		307
Research and development expenses							
Research and development expenses							
Intangible asset impairments							
Intangible asset impairments							
Intangible asset impairments							
Restructuring and other costs							
Restructuring and other costs							
Restructuring and other costs	Restructuring and other costs		6		3		70
Operating loss			(236)		(1,218)		(158)
Operating income (loss)							

Operating income (loss)									
Operating income (loss)									
Other income and expenses:	Other income and expenses:								
Other income and expenses:									
Other income and expenses:									
Interest expense, net									
Interest expense, net									
Interest expense, net	Interest expense, net	18	14	58	41				
Other (income) expense, net	Other (income) expense, net	(4)	9	16	20				
Loss before income taxes		(250)	(1,241)	(232)	(1,063)				
Other (income) expense, net									
Other (income) expense, net									
Income (loss) before income taxes									
Income (loss) before income taxes									
Income (loss) before income taxes									
Provision (benefit) for income taxes									
Provision (benefit) for income taxes									
Provision (benefit) for income taxes	Provision (benefit) for income taxes	16	(164)	(28)	(128)				
Net loss		(266)	(1,077)	(204)	(935)				
Net income (loss)									
Net income (loss)									
Net income (loss)									
Less: Net loss attributable to noncontrolling interest	Less: Net loss attributable to noncontrolling interest	—	—	(5)	—				
Net loss attributable to Dentsply Sirona	\$	(266)	\$	(1,077)	\$	(199)	\$	(935)	
Less: Net loss attributable to noncontrolling interest									
Net loss per common share attributable to Dentsply Sirona:									
Less: Net loss attributable to noncontrolling interest									
Net income (loss) attributable to Dentsply Sirona									
Net income (loss) attributable to Dentsply Sirona									
Net income (loss) attributable to Dentsply Sirona									
Net income (loss) per common share attributable to Dentsply Sirona:									
Net income (loss) per common share attributable to Dentsply Sirona:									
Net income (loss) per common share attributable to Dentsply Sirona:									
Basic	Basic	\$	(1.25)	\$	(5.01)	\$	(0.94)	\$	(4.34)
Basic									
Basic									
Diluted									

Diluted									
Diluted	Diluted	\$	(1.25)	\$	(5.01)	\$	(0.94)	\$	(4.34)
Weighted average common shares outstanding:	Weighted average common shares outstanding:								
Weighted average common shares outstanding:									
Weighted average common shares outstanding:									
Basic									
Basic									
Basic	Basic	211.8	214.9	212.7	215.6				
Diluted	Diluted	211.8	214.9	212.7	215.6				
Diluted									
Diluted									

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE **INCOME (LOSS) LOSS**

(in millions)

(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Net loss	\$ (266)	\$ (1,077)	\$ (204)	\$ (935)
Other comprehensive loss, net of tax:				
Foreign currency translation loss	(64)	(148)	(49)	(310)
Net gain on derivative financial instruments	27	22	20	54
Pension liability gain	—	1	—	4
Total other comprehensive loss, net of tax	(37)	(125)	(29)	(252)
Total comprehensive loss	(303)	(1,202)	(233)	(1,187)
Less: Comprehensive loss attributable to noncontrolling interests	—	—	(5)	—
Total comprehensive loss attributable to Dentsply Sirona	\$ (303)	\$ (1,202)	\$ (228)	\$ (1,187)

	Three Months Ended March 31,	
	2024	2023
Net income (loss)	\$ 17	\$ (23)
Other comprehensive (loss) income, net of tax:		
Foreign currency translation (loss) gain	(62)	15
Net gain (loss) on derivative financial instruments	32	(1)
Pension liability gain	—	—
Total other comprehensive (loss) income, net of tax	(30)	14
Total comprehensive loss	(13)	(9)
Less: Comprehensive loss attributable to noncontrolling interests	(1)	(4)

Total comprehensive loss attributable to Dentsply Sirona	\$	(12)	\$	(5)
--	----	------	----	-----

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share amounts)

(unaudited)

		September 30, 2023	December 31, 2022		
	March 31, 2024			March 31, 2024	December 31, 2023
Assets	Assets				
Assets					
Assets					
Current Assets:					
Current Assets:					
Current Assets:	Current Assets:				
Cash and cash equivalents	Cash and cash equivalents	\$ 309	\$ 365		
Accounts and notes receivables-trade, net		649	632		
Cash and cash equivalents					
Cash and cash equivalents					
Accounts and notes receivable-trade, net					
Inventories, net	Inventories, net	651	627		
Prepaid expenses and other current assets	Prepaid expenses and other current assets	304	269		
Total Current Assets	Total Current Assets	1,913	1,893		
Property, plant, and equipment, net					
Property, plant, and equipment, net					
Property, plant, and equipment, net	Property, plant, and equipment, net	753	761		
Operating lease right-of-use assets, net	Operating lease right-of-use assets, net	182	200		
Identifiable intangible assets, net	Identifiable intangible assets, net	1,711	1,903		
Goodwill	Goodwill	2,374	2,688		
Other noncurrent assets	Other noncurrent assets	268	198		
Total Assets	Total Assets	\$ 7,201	\$ 7,643		
Liabilities and Equity	Liabilities and Equity				
Liabilities and Equity					

Current Liabilities:	Current Liabilities:		
Current Liabilities:			
Accounts payable			
Accounts payable			
Accounts payable	Accounts payable	\$ 262	\$ 279
Accrued liabilities	Accrued liabilities	732	727
Income taxes payable	Income taxes payable	37	46
Notes payable and current portion of long-term debt	Notes payable and current portion of long-term debt	187	118
Total Current Liabilities	Total Current Liabilities	1,218	1,170
Long-term debt	Long-term debt	1,803	1,826
Long-term debt			
Long-term debt			
Operating lease liabilities	Operating lease liabilities	133	149
Deferred income taxes	Deferred income taxes	249	287
Other noncurrent liabilities	Other noncurrent liabilities	427	399
Total Liabilities	Total Liabilities	3,830	3,831
Commitments and contingencies (Note 14)	Commitments and contingencies (Note 14)		
Commitments and contingencies (Note 14)			
Commitments and contingencies (Note 14)			
Equity:	Equity:		
Equity:			
Equity:			
Preferred stock, \$1.00 par value; 0.25 million shares authorized; no shares issued			
Preferred stock, \$1.00 par value; 0.25 million shares authorized; no shares issued			
Preferred stock, \$1.00 par value; 0.25 million shares authorized; no shares issued	Preferred stock, \$1.00 par value; 0.25 million shares authorized; no shares issued	—	—
Common stock, \$0.01 par value;	Common stock, \$0.01 par value;	3	3

400.0 million shares authorized, and 264.5 million shares issued at September 30, 2023 and December 31, 2022			
211.8 million and 215.3 million shares outstanding at September 30, 2023 and December 31, 2022			
400.0 million shares authorized, and 264.5 million shares issued at March 31, 2024 and December 31, 2023			
207.6 million and 207.2 million shares outstanding at March 31, 2024 and December 31, 2023			
207.6 million and 207.2 million shares outstanding at March 31, 2024 and December 31, 2023			
207.6 million and 207.2 million shares outstanding at March 31, 2024 and December 31, 2023			
Capital in excess of par value			
Capital in excess of par value			
Capital in excess of par value	Capital in excess of par value	6,645	6,629
Retained earnings	Retained earnings	167	456
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(657)	(628)
Treasury stock, at cost, 52.7 million and 49.3 million shares at September 30, 2023 and December 31, 2022, respectively			
(2,783)			
(2,649)			
Treasury stock, at cost, 56.9 million and 57.3 million shares at March 31, 2024 and December 31, 2023, respectively			
Total Dentsply Sirona Equity	Total Dentsply Sirona Equity	3,375	3,811
Noncontrolling interests	Noncontrolling interests	(4)	1
Noncontrolling interests			

Noncontrolling interests			
Total Equity	Total Equity	3,371	3,812
Total Liabilities and Equity	Total Liabilities and Equity	\$ 7,201	\$ 7,643

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in millions, except per share amounts)

(unaudited)

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
Balance at December 31, 2022	\$ 3	\$ 6,629	\$ 456	\$ (628)	\$ (2,649)	\$ 3,811	\$ 1	\$ 3,812
Net loss	—	—	(19)	—	—	(19)	(4)	(23)
Other comprehensive income	—	—	—	14	—	14	—	14
Stock based compensation expense	—	17	—	—	—	17	—	17
Funding of employee stock purchase plan	—	—	—	—	3	3	—	3
Accelerated share repurchase	—	(30)	—	—	(121)	(151)	—	(151)
Restricted stock unit distributions	—	(12)	—	—	8	(4)	—	(4)
Cash dividends declared (\$0.14 per share)	—	—	(30)	—	—	(30)	—	(30)
Balance at March 31, 2023	\$ 3	\$ 6,604	\$ 407	\$ (614)	\$ (2,759)	\$ 3,641	\$ (3)	\$ 3,638
Net income (loss)	—	—	86	—	—	86	(1)	85
Other comprehensive loss	—	—	—	(6)	—	(6)	—	(6)
Exercise of stock options	—	—	—	—	1	1	—	1
Stock based compensation expense	—	14	—	—	—	14	—	14
Accelerated share repurchase	—	30	—	—	(30)	—	—	—
Restricted stock unit dividends	—	—	(1)	—	—	(1)	—	(1)
Cash dividends declared (\$0.14 per share)	—	—	(29)	—	—	(29)	—	(29)
Balance at June 30, 2023	\$ 3	\$ 6,648	\$ 463	\$ (620)	\$ (2,788)	\$ 3,706	\$ (4)	\$ 3,702
Net loss	—	—	(266)	—	—	(266)	—	(266)
Other comprehensive loss	—	—	—	(37)	—	(37)	—	(37)
Stock based compensation expense	—	2	—	—	—	2	—	2
Funding of employee stock purchase plan	—	(1)	—	—	3	2	—	2
Restricted stock unit distributions	—	(4)	—	—	2	(2)	—	(2)
Cash dividends (\$0.14 per share)	—	—	(30)	—	—	(30)	—	(30)
Balance at September 30, 2023	\$ 3	\$ 6,645	\$ 167	\$ (657)	\$ (2,783)	\$ 3,375	\$ (4)	\$ 3,371

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
Balance at December 31, 2023	\$ 3	\$ 6,643	\$ 205	\$ (636)	\$ (2,922)	\$ 3,293	\$ 1	\$ 3,294
Net income (loss)	—	—	18	—	—	18	(1)	17
Other comprehensive loss	—	—	—	(30)	—	(30)	—	(30)
Stock based compensation expense	—	11	—	—	—	11	—	11
Funding of employee stock purchase plan	—	—	—	—	3	3	—	3

Restricted stock unit distributions	—	(15)	—	—	11	(4)	—	(4)
Cash dividends declared (\$0.16 per share)	—	—	(33)	—	—	(33)	—	(33)
Balance at March 31, 2024	\$ 3	\$ 6,639	\$ 190	\$ (666)	\$ (2,908)	\$ 3,258	\$ —	\$ 3,258

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
Balance at December 31, 2021	\$ 3	\$ 6,606	\$ 1,514	\$ (592)	\$ (2,535)	\$ 4,996	\$ 1	\$ 4,997
Net income	—	—	69	—	—	69	—	69
Other comprehensive loss	—	—	—	(37)	—	(37)	—	(37)
Exercise of stock options	—	1	—	—	4	5	—	5
Stock based compensation expense	—	11	—	—	—	11	—	11
Funding of employee stock purchase plan	—	1	—	—	1	2	—	2
Accelerated share repurchase	—	(30)	—	—	(120)	(150)	—	(150)
Restricted stock unit distributions	—	(16)	—	—	10	(6)	—	(6)
Cash dividends declared (\$0.125 per share)	—	—	(27)	—	—	(27)	—	(27)
Balance at March 31, 2022	\$ 3	\$ 6,573	\$ 1,556	\$ (629)	\$ (2,640)	\$ 4,863	\$ 1	\$ 4,864
Net income	—	—	73	—	—	73	—	73
Other comprehensive loss	—	—	—	(90)	—	(90)	—	(90)
Exercise of stock options	—	—	—	—	2	2	—	2
Stock based compensation expense	—	16	—	—	—	16	—	16
Accelerated share repurchase	—	30	—	—	(30)	—	—	—
Funding of employee stock purchase plan	—	—	—	—	1	1	—	1
Restricted stock unit distributions	—	(3)	—	—	1	(2)	—	(2)
Restricted stock unit dividends	—	1	(1)	—	—	—	—	—
Cash dividends declared (\$0.125 per share)	—	—	(26)	—	—	(26)	—	(26)
Balance at June 30, 2022	\$ 3	\$ 6,617	\$ 1,602	\$ (719)	\$ (2,666)	\$ 4,837	\$ 1	\$ 4,838
Net loss	—	—	(1,077)	—	—	(1,077)	—	(1,077)
Other comprehensive loss	—	—	—	(125)	—	(125)	—	(125)
Stock based compensation expense	—	3	—	—	—	3	—	3
Funding of employee stock purchase plan	—	—	—	—	3	3	—	3
Restricted stock unit distributions	—	(1)	—	—	—	(1)	—	(1)
Cash dividends (\$0.125 per share)	—	—	(27)	—	—	(27)	—	(27)
Balance at September 30, 2022	\$ 3	\$ 6,619	\$ 498	\$ (844)	\$ (2,663)	\$ 3,613	\$ 1	\$ 3,614

	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Total Dentsply Sirona Equity	Noncontrolling Interests	Total Equity
Balance at December 31, 2022	\$ 3	\$ 6,629	\$ 456	\$ (628)	\$ (2,649)	\$ 3,811	\$ 1	\$ 3,812
Net income (loss)	—	—	(19)	—	—	(19)	(4)	(23)
Other comprehensive income	—	—	—	14	—	14	—	14
Stock based compensation expense	—	17	—	—	—	17	—	17
Funding of employee stock purchase plan	—	—	—	—	3	3	—	3

Indefinite-lived intangible asset impairment			
Indefinite-lived intangible asset impairment	Indefinite-lived intangible asset impairment	16	94
Deferred income taxes			
Deferred income taxes			
Deferred income taxes	Deferred income taxes	(107)	(220)
Stock based compensation expense	Stock based compensation expense	33	47
Restructuring and other costs	Restructuring and other costs	39	(5)
Other non-cash expense	Other non-cash expense	29	38
Other non-cash expense			
Other non-cash expense			
Changes in operating assets and liabilities, net of acquisitions:	Changes in operating assets and liabilities, net of acquisitions:		
Changes in operating assets and liabilities, net of acquisitions:			
Changes in operating assets and liabilities, net of acquisitions:			
Accounts and notes receivable-trade, net			
Accounts and notes receivable-trade, net			
Accounts and notes receivable-trade, net	Accounts and notes receivable-trade, net	(31)	43
Inventories, net	Inventories, net	(45)	(140)
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(52)	(46)
Other noncurrent assets	Other noncurrent assets	(4)	(13)
Accounts payable	Accounts payable	(10)	40
Accrued liabilities	Accrued liabilities	(23)	3
Income taxes	Income taxes	(6)	41

Other noncurrent liabilities	Other noncurrent liabilities	33	(8)
Net cash provided by operating activities			
		217	375
Net cash provided by (used in) operating activities			
Cash flows from investing activities:	Cash flows from investing activities:		
Cash flows from investing activities:			
Cash flows from investing activities:			
Capital expenditures			
Capital expenditures			
Capital expenditures	Capital expenditures	(109)	(117)
Cash received on derivative contracts	Cash received on derivative contracts	39	10
Cash received on derivative contracts			
Cash received on derivative contracts			
Cash paid on derivative contracts			
Other investing activities		1	(2)
Net cash used in investing activities			
Net cash used in investing activities			
Net cash used in investing activities	Net cash used in investing activities	(69)	(109)
Cash flows from financing activities:	Cash flows from financing activities:		
Cash flows from financing activities:			
Cash flows from financing activities:			
Cash paid for treasury stock			
Cash paid for treasury stock			
Cash paid for treasury stock	Cash paid for treasury stock	(150)	(150)
Proceeds on short-term borrowings	Proceeds on short-term borrowings	68	64
Cash dividends paid	Cash dividends paid	(86)	(78)

Proceeds from long-term borrowings, net of deferred financing costs		2	7
Repayments on long-term borrowings	Repayments on long-term borrowings	(6)	(2)
Proceeds from exercised stock options		—	6
Repayments on long-term borrowings			
Repayments on long-term borrowings			
Other financing activities, net	Other financing activities, net	(7)	(15)
Net cash used in financing activities		(179)	(168)
Other financing activities, net			
Other financing activities, net			
Net cash (used in) provided by financing activities			
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(25)	(19)
Net (decrease) increase in cash and cash equivalents		(56)	79
Net decrease in cash and cash equivalents			
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	365	339
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	\$ 309	\$ 418

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA Inc. and Subsidiaries

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BUSINESS AND BASIS OF PRESENTATION

Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and the rules of the U.S. Securities and Exchange Commission ("SEC"). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries ("Dentsply Sirona" or the "Company") on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company's most recent Form 10-K/A 10-K for the year ended December 31, 2022 December 31, 2023, filed with the Securities and Exchange Commission on August 7, 2023 February 29, 2024 (the "2022" "2023" Form 10-K/A" 10-K").

Effective April 1, 2023 the Company realigned its reporting structure due to certain organizational changes. As a result, the Company's reportable segments changed from Technology & Equipment and Consumables to (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect

Healthcare. All comparative segment information and disaggregated revenue information has been recast to reflect the Company's new segment structure and current period presentation. Refer to Note 6, Segment Information, for further discussion on this change.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates.

Recently Adopted Accounting Pronouncements Not Yet Adopted

In October 2021, November 2023, the Financial Accounting Standards Board ("FASB") FASB issued ASU No. 2021-08, "Business Combinations 2023-07, "Segment Reporting (Topic 805) 280): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, Improvements to Reportable Segment Disclosures," which requires contract assets public entities to disclose information about significant expenses in their reportable segment results on both an interim and contract liabilities acquired annual basis. Public entities are required to disclose significant expense categories and amounts for each reportable segment. Significant expense categories are derived from expenses that are regularly reported to an entity's chief operating decision-maker ("CODM") and included in a business combination segment's reported measures of profit or loss. Public entities are also required to disclose the title and position of the CODM and explain how the CODM uses the reported measures of profit or loss to assess segment performance. This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 and early adoption is permitted and should be recognized applied retrospectively for all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact on its consolidated financial statements and measured by related disclosures.

In December 2023, the acquirer FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which requires public entities to disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid on an annual basis. The amendment in the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated ASU is intended to enhance the contracts. The new standard requirement to measure contract assets transparency and contract liabilities acquired in a business combination at fair value differs from the current approach, decision usefulness of income tax disclosures. The amendments in this update were are effective for the fiscal years annual periods beginning after December 15, 2024, and interim periods ending after December 31, 2022, early adoption is permitted and should be applied prospectively. The Company adopted this accounting standard is currently evaluating the impact on January 1, 2023. The adoption of this standard did not materially impact the Company's its consolidated financial statements or related disclosures.

In March 2020, the FASB issued ASU No. 2020-04 "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting," which was subsequently amended by ASU No. 2021-01 "Reference Rate Reform (Topic 848): Scope" in January 2021 and by ASU No. 2022-06 "Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848" in December 2022. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate or another rate expected to be discontinued due to the reference rate reform. This standard was effective upon issuance. The adoption of this standard did not materially impact the Company's consolidated financial statements or related disclosures.

Seasonality

Our business is subject to quarterly fluctuations in demand due to price changes, marketing and promotional programs, management of inventory levels by distributors and other customers, and implementation of strategic initiatives which may impact sales levels in any given period. Demand can also fluctuate based on the timing of dental tradeshow, new product introductions, and variability in dental patient traffic, which can be exacerbated by seasonal or severe weather patterns, other demographic disruptions, macroeconomic conditions, or macroeconomic conditions, other factors. Some dental practices in certain countries may also delay purchasing equipment and restocking consumables until year-end due to tax or other financial planning reasons which can impact the timing of our consolidated net sales, net income and cash flows. Sales for the industry and the Company are generally strongest in the second and fourth quarters and weaker in the first and third quarters, due to the effects of the items noted above and due to the impact of holidays and vacations, particularly throughout Europe. Because of the seasonal nature of our business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year.

NOTE 2 - REVENUE

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 were as follows:

		Three Months Ended		Nine Months Ended	
		Three Months Ended			
		Three Months Ended			
		Three Months Ended			
(in millions)					
(in millions)					
(in millions)	(in millions)	2023	2022	2023	2022
Equipment & Instruments	Equipment & Instruments	\$ 148	\$ 163	\$ 480	\$ 498
Equipment & Instruments					

Equipment & Instruments					
CAD/CAM	CAD/CAM	128	123	370	377
CAD/CAM					
CAD/CAM					
Connected Technology Solutions					
Connected Technology Solutions					
Connected Technology Solutions	Connected Technology Solutions	\$ 276	\$ 286	\$ 850	\$ 875
Essential Dental Solutions	Essential Dental Solutions	\$ 347	\$ 348	\$ 1,110	\$ 1,084
Essential Dental Solutions					
Essential Dental Solutions					
Orthodontics					
Orthodontics					
Orthodontics	Orthodontics	\$ 83	\$ 76	\$ 255	\$ 220
Implants & Prosthetics	Implants & Prosthetics	169	171	526	552
Implants & Prosthetics					
Implants & Prosthetics					
Orthodontic and Implant Solutions					
Orthodontic and Implant Solutions					
Orthodontic and Implant Solutions	Orthodontic and Implant Solutions	\$ 252	\$ 247	\$ 781	\$ 772
Wellspect Healthcare	Wellspect Healthcare	\$ 72	\$ 66	\$ 212	\$ 208
Wellspect Healthcare					
Wellspect Healthcare					
Total net sales	Total net sales	\$ 947	\$ 947	\$ 2,953	\$ 2,939
Total net sales					
Total net sales					

Net sales disaggregated by geographic region for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022** 2023 were as follows:

		Three Months Ended		Nine Months Ended	
		Three Months Ended			
		Three Months Ended			
		Three Months Ended			
(in millions)					
(in millions)					
(in millions)	(in millions)	2023	2022	2023	2022
United States	United States	\$ 356	\$ 357	\$ 1,069	\$ 1,023
United States					
United States					
Europe	Europe	354	358	1,153	1,183
Europe					
Europe					
Rest of World					
Rest of World					
Rest of World	Rest of World	237	232	731	733
Total net sales	Total net sales	\$ 947	\$ 947	\$ 2,953	\$ 2,939
Total net sales					

Total net sales

Contract Assets and Liabilities

The Company does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer **orthodontic aligner treatment treatments** where the performance obligation has not yet been fulfilled. The Company **had recorded** deferred revenue of **\$87 million** **\$102 million** and **\$54 million** **recorded** **\$59 million** in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at **September 30, 2023** **March 31, 2024**. The Company **had recorded** deferred revenue of **\$91 million** and **\$27** **\$57 million** **recorded** in Accrued liabilities and Other noncurrent liabilities, respectively, in the Consolidated Balance Sheets at **December 31, 2022** **December 31, 2023**. The Company recognized **approximately \$59 million of revenue** **approximately \$41 million of net sales** during the **current year** **three months ended March 31, 2024** which was previously deferred as of **December 31, 2022** **December 31, 2023**. The Company expects to recognize a majority of the remaining deferred revenue **in net sales** within the next twelve months.

Allowance for Doubtful Accounts

Accounts and notes **receivables-trade, receivable-trade**, net are stated net of allowances for doubtful accounts and trade discounts, which were **\$13 million** **\$17 million** at **September 30, 2023** **March 31, 2024** and **\$14 million** **\$17 million** at **December 31, 2022** **December 31, 2023**. For the three **and nine** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023**, changes to the provision for doubtful accounts, including write-offs of accounts receivable that were previously reserved, were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.

NOTE 3 – STOCK COMPENSATION

The amounts of stock compensation expense recorded in the Company's Consolidated Statements of Operations for the three **and nine** months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** were as follows:

		Three Months Ended		Nine Months Ended	
		Three Months Ended		Three Months Ended	
		Three Months Ended		Three Months Ended	
		Three Months Ended		Three Months Ended	
(in millions)					
(in millions)					
(in millions)	(in millions)	2023	2022	2023	2022
Cost of products sold	Cost of products sold	\$ 1	\$ 1	\$ 3	\$ 2
Cost of products sold	Cost of products sold				
Selling, general, and administrative expense	Selling, general, and administrative expense				
Selling, general, and administrative expense	Selling, general, and administrative expense				
Selling, general, and administrative expense	Selling, general, and administrative expense	1	12	25	43
Research and development expense	Research and development expense	1	1	3	2
Research and development expense	Research and development expense				
Restructuring and other costs	Restructuring and other costs	(1)	—	2	—
Restructuring and other costs	Restructuring and other costs				
Total stock based compensation expense	Total stock based compensation expense				
Total stock based compensation expense	Total stock based compensation expense				
Total stock based compensation expense	Total stock based compensation expense	\$ 2	\$ 14	\$ 33	\$ 47
Related deferred income tax benefit	Related deferred income tax benefit	\$ 2	\$ 1	\$ 5	\$ 4

Related deferred income tax benefit

Related deferred income tax benefit

NOTE 4 – COMPREHENSIVE INCOME (LOSS)

Changes in Accumulated other comprehensive income (loss) ("AOCI" ("AOCI"), net of tax, by component for the **nine three** months ended **September 30, 2023** **March 31, 2024** and **2022 2023** were as follows:

(in millions)	Foreign Currency Translation Gain (Loss)	Gain (Loss) on Cash Flow Hedges	Gain (Loss) on Net Investment and Fair Value Hedges	Pension Liability Gain (Loss)	Total
Balance, net of tax, at December 31, 2022	\$ (522)	\$ (17)	\$ (73)	\$ (16)	\$ (628)
Other comprehensive income (loss) before reclassifications and tax impact	6	(1)	—	—	5
Tax benefit	9	—	—	—	9
Other comprehensive income (loss), net of tax, before reclassifications	15	(1)	—	—	14
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	—	—	—	—
Net increase (decrease) in other comprehensive income	15	(1)	—	—	14
Balance, net of tax, at March 31, 2023	\$ (507)	\$ (18)	\$ (73)	\$ (16)	\$ (614)
Other comprehensive loss before reclassifications and tax impact	(3)	—	(11)	—	(14)
Tax benefit	3	—	3	—	6
Other comprehensive loss, net of tax, before reclassifications	—	—	(8)	—	(8)
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	2	—	—	2
Net increase (decrease) in other comprehensive income	—	2	(8)	—	(6)
Balance, net of tax, at June 30, 2023	\$ (507)	\$ (16)	\$ (81)	\$ (16)	\$ (620)
Other comprehensive (loss) income before reclassifications and tax impact	(60)	1	33	—	(26)
Tax expense	(4)	—	(8)	—	(12)
Other comprehensive (loss) benefit, net of tax, before reclassifications	(64)	1	25	—	(38)
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	1	—	—	1
Net (decrease) increase in other comprehensive income	(64)	2	25	—	(37)
Balance, net of tax, at September 30, 2023	\$ (571)	\$ (14)	\$ (56)	\$ (16)	\$ (657)

(in millions)	Foreign Currency Translation Gain (Loss)	Gain (Loss) on Cash Flow Hedges	Gain (Loss) on Net Investment and Fair Value Hedges	Pension Liability Gain (Loss)	Total
Balance, net of tax, at December 31, 2023	\$ (473)	\$ (13)	\$ (107)	\$ (43)	\$ (636)
Other comprehensive income (loss) before reclassifications and tax impact	(34)	—	42	—	8
Tax expense	(28)	—	(10)	—	(38)
Other comprehensive income (loss), net of tax, before reclassifications	(62)	—	32	—	(30)
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	—	—	—	—
Net increase (decrease) in other comprehensive income	(62)	—	32	—	(30)
Balance, net of tax, at March 31, 2024	\$ (535)	\$ (13)	\$ (75)	\$ (43)	\$ (666)

		Foreign Currency Translation Gain (Loss)	Gain (Loss) on Cash Flow Hedges	Gain (Loss) on Investment and Fair Value Hedges	Pension Liability Gain (Loss)	Total
(in millions)	(in millions)					
(in millions)						
			Foreign Currency Translation Gain (Loss)	Gain (Loss) on Cash Flow Hedges	Gain (Loss) on Net Investment and Fair Value Hedges	Pension Liability Gain (Loss) Total
(in millions)						
Balance, net of tax, at December 31, 2021		\$ (366)	\$ (16)	\$ (103)	\$ (107)	\$(592)
Balance, net of tax, at December 31, 2022						
Balance, net of tax, at December 31, 2022						
Balance, net of tax, at December 31, 2022						
Other comprehensive (loss) income before reclassifications and tax impact	Other comprehensive (loss) income before reclassifications and tax impact	(37)	3	9	—	(25)
Tax expense		(11)	—	(1)	—	(12)
Tax benefit						
Other comprehensive (loss) income, net of tax, before reclassifications	Other comprehensive (loss) income, net of tax, before reclassifications	(48)	3	8	—	(37)
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	(1)	—	1	—
Net (decrease) increase in other comprehensive income	Net (decrease) increase in other comprehensive income	(48)	2	8	1	(37)
Balance, net of tax, at March 31, 2022		\$ (414)	\$ (14)	\$ (95)	\$ (106)	\$(629)
Other comprehensive (loss) income before reclassifications and tax impact		(86)	(3)	32	—	(57)
Tax expense		(28)	—	(8)	—	(36)
Other comprehensive (loss) income, net of tax, before reclassifications		(114)	(3)	24	—	(93)

Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	1	—	2	3
Net (decrease) increase in other comprehensive income	(114)	(2)	24	2	(90)
Balance, net of tax, at March 31, 2023					
Balance, net of tax, at June 30, 2022	\$ (528)	\$ (16)	\$ (71)	\$ (104)	\$ (719)
Other comprehensive (loss) income before reclassifications and tax impact	(120)	3	28	—	(89)
Tax expense	(28)	(1)	(7)	—	(36)
Other comprehensive (loss) income, net of tax, before reclassifications	(148)	2	21	—	(125)
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	—	(1)	—	1	—
Net (decrease) increase in other comprehensive income	(148)	1	21	1	(125)
Balance, net of tax, at September 30, 2022	\$ (676)	\$ (15)	\$ (50)	\$ (103)	\$ (844)

At September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, the cumulative tax adjustments were \$103 million \$128 million and \$100 million \$166 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of \$497 million \$452 million and \$438 million \$360 million at September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, respectively, and cumulative losses on loans designated as hedges of net investments of \$74 million \$83 million and \$84 million \$113 million, respectively.

Reclassifications out of AOCI to the Consolidated Statements of Operations for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 were not significant.

NOTE 5 – EARNINGS (LOSS) PER COMMON SHARE

The computation of basic and diluted earnings (loss) per common share for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 were 2023 was as follows:

Basic Earnings Per Common Share		Three Months Ended		Nine Months Ended		
Basic Earnings (Loss) Per Common Share						
Basic Earnings (Loss) Per Common Share						
Basic Earnings (Loss) Per Common Share						
(in millions, except per share amounts)						
(in millions, except per share amounts)						
(in millions, except per share amounts)	(in millions, except per share amounts)	2023	2022	2023	2022	
Net loss attributable to Dentsply Sirona	\$	(266)	\$	(199)	\$	(935)
Net income (loss) attributable to Dentsply Sirona						
Net income (loss) attributable to Dentsply Sirona						

Net income (loss) attributable to Dentsply Sirona					
Weighted average common shares outstanding	Weighted average common shares outstanding	211.8	214.9	212.7	215.6
Loss per common share - basic		\$ (1.25)	\$ (5.01)	\$ (0.94)	\$ (4.34)
Weighted average common shares outstanding					
Diluted Earnings Per Common Share		Three Months Ended		Nine Months Ended	
Weighted average common shares outstanding					
Earnings (loss) per common share - basic					
Earnings (loss) per common share - basic					
Earnings (loss) per common share - basic					
Diluted Earnings (Loss) Per Common Share					
Diluted Earnings (Loss) Per Common Share					
Diluted Earnings (Loss) Per Common Share					
(in millions, except per share amounts)					
(in millions, except per share amounts)					
(in millions, except per share amounts)	(in millions, except per share amounts)	2023	2022	2023	2022
Net loss attributable to Dentsply Sirona		\$ (266)	\$ (1,077)	\$ (199)	\$ (935)
Net income (loss) attributable to Dentsply Sirona					
Net income (loss) attributable to Dentsply Sirona					
Net income (loss) attributable to Dentsply Sirona					
Weighted average common shares outstanding					
Weighted average common shares outstanding					
Weighted average common shares outstanding	Weighted average common shares outstanding	211.8	214.9	212.7	215.6
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—	—	—	—
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards					
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards					
Total weighted average diluted shares outstanding					

Total weighted average diluted shares outstanding								
Total weighted average diluted shares outstanding	Total weighted average diluted shares outstanding	211.8	214.9	212.7	215.6			
Loss per common share - diluted	\$	(1.25)	\$	(5.01)	\$	(0.94)	\$	(4.34)
Earnings (loss) per common share - diluted								
Weighted average shares excluded from diluted common shares outstanding due to reported net loss					1.1	0.3	1.1	0.5
Earnings (loss) per common share - diluted								
Earnings (loss) per common share - diluted								
Weighted average shares excluded from diluted common shares outstanding due to reported net loss for the period								
Weighted average shares excluded from diluted common shares outstanding due to reported net loss for the period								
Weighted average shares excluded from diluted common shares outstanding due to reported net loss for the period								
Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature	Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature	3.0	3.6	3.4	3.6			
Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature								
Weighted average shares excluded from diluted common shares outstanding due to antidilutive nature								

On July 28, 2021 November 7, 2023, the Board of Directors approved a an increase to the authorized share repurchase program of up to \$1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company deems considers appropriate based upon prevailing market and business conditions and other factors. At September 30, 2023 March 31, 2024, the Company had authorization to repurchase \$590 million \$1.44 billion in shares of common stock remaining under the share repurchase program.

On March 3, 2023, the Company entered into an Accelerated Share Repurchase Agreement ("ASR Agreement") with a financial institution to repurchase the Company's common stock. The Company repurchased shares under the ASR Agreement as part of the share repurchase program described above. During the nine months ended September 30, 2023, the Company repurchased approximately 3.1 million shares delivered during March 2023 at a volume-weighted average price of \$38.74 representing \$120 million of the total anticipated repurchase. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement resulting in a total of 3.9 million shares repurchased under the agreement.

(in millions, except per share amounts)		Initial Delivery			Final Settlement		
Agreement Date	Amount Paid	Shares Received	Price per share	Value of Shares as a % of Contract Value	Settlement Date	Total Shares Received	Average Price per Share
March 3, 2023	\$ 150	3.1	\$ 38.74	80 %	April 28, 2023	3.9	\$ 38.55

The ASR Agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March 6, 2023 of \$121 million and a forward contract indexed to the Company's common stock for an amount of common shares that was determined on the final settlement date. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument for the quarter ended March 31, 2023. Therefore, the value of the forward contract of \$30 million was recorded in Capital in excess of par value at March 31, 2023. Upon final settlement in April 2023, this amount was subsequently recorded as Treasury Stock in the Consolidated Balance Sheets. The initial delivery and final settlement of common stock reduced the weighted average common shares outstanding for both basic and diluted earnings per share. The

forward contract did not impact the weighted average common shares outstanding for diluted earnings per share. The treasury stock transactions included an excise tax accrual of \$1 million for public company stock repurchases established by the Inflation Reduction Act (IRA) of 2022.

NOTE 6 – SEGMENT INFORMATION

Effective April 1, 2023 the Company realigned its reporting structure due to certain organizational changes. The Company has realigned its reportable segments to reflect changes in how the Company manages its operations, specifically the level at which its chief operating decision maker ("CODM") regularly reviews operating results and allocates resources. As a result, the reportable segments changed from Technology & Equipment and Consumables to (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare.

Segment Descriptions

A description of the products and services provided within each of the Company's four reportable segments under the new structure is provided below.

Connected Technology Solutions

This segment is responsible for the design, manufacture and sales of the Company's dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories.

Equipment & Instruments

The Equipment & Instruments product category consists of basic and high-tech dental equipment such as imaging equipment, motorized dental handpieces, treatment centers, and other instruments for dental practitioners and specialists. Imaging equipment serves as the point of entry to the Company's digital workflow offerings and consists of a broad range of diagnostic imaging systems for 2D or 3D, panoramic, and intra-oral applications, as well as cone-beam computed tomography systems (CBCT). Treatment centers comprise a broad range of products from basic dental chairs to sophisticated chair-based units with integrated diagnostic, hygienic and ergonomic functionalities, as well as specialist centers used in preventive treatment and for training purposes. This product group also includes other lab equipment such as amalgamators, mixing machines and porcelain furnaces.

CAD/CAM

Dental CAD/CAM technologies are products designed for dental offices to support numerous digital dental procedures including dental restorations. This product category includes a full-chairside economical restoration of esthetic ceramic dentistry offering called CEREC, as well as stand-alone CAD/CAM, digital impressions ("DI") intra-oral scanners, 3-D printer mills, and certain software and services. A full-chairside offering enables dentists to practice same day or single visit dentistry.

Essential Dental Solutions

This segment is responsible for the design, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used in dental offices for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.

Essential Dental Solutions products are designed to operate in an integrated system to provide solutions for high-tech dental procedures. The endodontic products include drills, files, sealers, irrigation needles and other tools or single-use solutions which support root canal procedures. The restorative products include dental ceramic offerings.

The preventive products include small equipment products such as intraoral curing light systems, dental diagnostic systems and ultrasonic scalers and polishers, as well as other dental supplies including dental anesthetics, prophylaxis paste, dental sealants and impression materials.

Orthodontic and Implant Solutions

This segment is responsible for the design, manufacture, and sale of the Company's various digital implant systems and innovative dental implant products, digital dentures and dentist directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by our cloud-based platform.

Orthodontics

The Orthodontics product category includes an in-office aligner solution, SureSmile, and a direct-to-consumer aligner solution, Byte. The Orthodontics product category also includes a High Frequency Vibration technology device known as VPro or as HyperByte within Byte's product offering. The aligner offerings include software technology that enables aligner treatment planning and seamless connectivity of a digital workflow from diagnostics through treatment delivery.

Implants & Prosthetics

The Implants & Prosthetics product category includes technology to support the Company's digital workflows for implant systems, a portfolio of innovative dental implant products, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software and educational programs. The Implants & Prosthetics product category is supported by key technologies including custom abutments, advanced tapered immediate load screws and regenerative bone growth factor. Offerings in this segment also include dental prosthetics such as artificial teeth and precious metal dental alloys.

Wellspect Healthcare

This segment is responsible for the design, manufacture, and sale of the Company's innovative continence care solutions for both urinary and bowel management. This category consists mainly of urology catheters and other healthcare-related consumable products.

Segment Performance

The Company's four operating segments that are organized primarily by product. They generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight with the exception of Wellspect Healthcare, which has a more discreet discrete market and regulatory environment specific to the industry for medical devices, device industry. These operating segments, which also form the Company's reportable segments, are identified in accordance with how the Company's CODM regularly reviews financial results and uses this information to evaluate the Company's performance and allocate resources.

The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, goodwill and intangible asset impairments, restructuring and other costs, interest expense, net, other expense (income), net, amortization of intangible assets, and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions, business combinations. Asset and other balance sheet information are not reported to the CODM.

The Company's segment information for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 was as follows:

Net Sales

(in millions)	Three Months Ended		Nine Months Ended	
	2023	2022	2023	2022
Connected Technology Solutions	\$ 276	\$ 286	\$ 850	\$ 875
Essential Dental Solutions	347	348	1,110	1,084
Orthodontic and Implant Solutions	252	247	781	772
Wellspect Healthcare	72	66	212	208
Total net sales	\$ 947	\$ 947	\$ 2,953	\$ 2,939

(in millions)	Three Months Ended	
	2024	2023
Connected Technology Solutions	\$ 247	\$ 265
Essential Dental Solutions	364	386
Orthodontic and Implant Solutions	271	259
Wellspect Healthcare	71	68
Total net sales	\$ 953	\$ 978

Segment Adjusted Operating Income

		Three Months Ended		Nine Months Ended	
		Three Months Ended		Three Months Ended	
		Three Months Ended		Three Months Ended	
		Three Months Ended		Three Months Ended	
(in millions)	(in millions)	2023	2022	2023	2022
Connected Technology Solutions	Connected Technology Solutions	\$ 22	\$ 25	\$ 54	\$ 101
Connected Technology Solutions					
Connected Technology Solutions					
Essential Dental Solutions					
Essential Dental Solutions					
Essential Dental Solutions	Essential Dental Solutions	115	110	365	361
Orthodontic and Implant Solutions	Orthodontic and Implant Solutions	31	40	129	157
Orthodontic and Implant Solutions					

Orthodontic and Implant Solutions						
Wellspect Healthcare	Wellspect Healthcare	26	19	65	57	
Wellspect Healthcare						
Wellspect Healthcare						
Segment adjusted operating income						
Segment adjusted operating income						
Segment adjusted operating income	Segment adjusted operating income	194	194	613	676	
Reconciling items expense (income):	Reconciling items expense (income):					
Reconciling items expense (income):						
Reconciling items expense (income):						
All other (a)	All other (a)	63	77	233	223	
Goodwill and intangible asset impairments		307	1,281	307	1,281	
All other (a)						
All other (a)						
Intangible asset impairments						
Intangible asset impairments						
Intangible asset impairments						
Restructuring and other costs						
Restructuring and other costs						
Restructuring and other costs	Restructuring and other costs	6	3	70	13	
Interest expense, net	Interest expense, net	18	14	58	41	
Interest expense, net						
Interest expense, net						
Other expense (income), net		(4)	9	16	20	
Other (income) expense, net						
Other (income) expense, net						
Other (income) expense, net						
Amortization of intangible assets	Amortization of intangible assets	53	51	159	159	
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations						
		1	—	2	2	
Loss before income taxes	\$	(250)	\$	(232)	\$	(1,063)
Amortization of intangible assets						
Amortization of intangible assets						
Income (loss) before income taxes						
Income (loss) before income taxes						
Income (loss) before income taxes						

(a) Includes the results of unassigned Corporate corporate headquarters costs.

NOTE 7 – INVENTORIES

Inventories, net were as follows:

(in millions)	(in millions)	September 30, 2023	December 31, 2022	(in millions)	March 31, 2024	December 31, 2023
---------------	---------------	--------------------	-------------------	---------------	----------------	-------------------

Raw materials and supplies	Raw materials and supplies	\$ 173	\$ 169
Raw materials and supplies			
Raw materials and supplies			
Work-in-process	Work-in-process	83	77
Finished goods	Finished goods	395	381
Inventories, net	Inventories, net	\$ 651	\$ 627

The Company's inventory reserve was \$105 million \$107 million at both March 31, 2024 and \$83 million at September 30, 2023 and December 31, 2022, respectively. December 31, 2023. Inventories are stated at the lower of cost and net realizable value.

NOTE 8 – RESTRUCTURING AND OTHER COSTS

Restructuring and other costs for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 were recorded in the Consolidated Statements of Operations as follows:

Affected Line Item							
Affected Line Item							
Affected Line Item	Affected Line Item	Three Months Ended	Nine Months Ended			Three Months Ended	
(in millions)	(in millions)	2023	2022	2023	2022	2024	2023
Cost of products sold	Cost of products sold						
Cost of products sold	Cost of products sold	\$ —	\$ —	\$ 4	\$ —		
Selling, general, and administrative expenses	Selling, general, and administrative expenses	1	—	2	—		
Restructuring and other costs	Restructuring and other costs	6	3	70	13		
Total restructuring and other costs	Total restructuring and other costs	\$ 7	\$ 3	\$ 76	\$ 13		
Total restructuring and other costs							
Total restructuring and other costs							

Restructuring and other costs of \$70 million \$1 million recorded in the first nine three months of 2023 consist 2024 consisted primarily of employee severance benefits and other restructuring costs related to the plan approved by the Board of Directors of the Company on February 14, 2023. This plan seeks to restructure the Company's business to improve operational performance and drive shareholder value creation through a new operating model with four operating segments, optimization of central functions and overall management infrastructure, and other efforts aimed at cost savings. The restructuring plan anticipates a reduction in the Company's global workforce of approximately 8% to 10%, subject to co-determination processes with employee representative groups in countries where required, which processes are now substantially complete. The Company expects to incur between \$115 million and \$135 million in one-time charges, comprising \$80 million to \$100 million in restructuring expenditures and charges, primarily related to employee transition, severance payments, employee benefits and facility closure costs, and \$35 million in other non-recurring costs which mostly consist of consulting, legal and other professional service fees. The plan is expected to be substantially completed by mid-2024 and we expect that the majority of these costs will be incurred as cash expenditures in 2023, 2024. The estimates of these charges and their timing are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur other charges or cash expenditures in connection with this plan which are not currently contemplated.

The liabilities associated with the Company's restructuring plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company's restructuring accruals at **September 30, 2023** **March 31, 2024** was as follows:

Severance								
Severance								
Severance								
Severance								
(in millions)	(in millions)	2022 and Prior Plans	2023 Plan	Total	(in millions)	2022 and Prior Plans	2023 Plan	Total
Balance at December 31, 2022		\$ 7	\$ —	\$ 7				
Balance at December 31, 2023								
Balance at December 31, 2023								
Balance at December 31, 2023								
Provisions	Provisions	2	56	58				
Amounts applied	Amounts applied	(4)	(19)	(23)				
Change in estimates	Change in estimates	(2)	6	4				
Balance at September 30, 2023		\$ 3	\$ 43	\$ 46				
Balance at March 31, 2024								
Other Restructuring Costs								
Other Restructuring Costs								
Other Restructuring Costs								
Other Restructuring Costs								
(in millions)	(in millions)	2022 and Prior Plans	2023 Plan	Total	(in millions)	2022 and Prior Plans	2023 Plan	Total
Balance at December 31, 2022		\$ 1	\$ —	\$ 1				
Balance at December 31, 2023								
Balance at December 31, 2023								
Balance at December 31, 2023								
Provisions	Provisions	1	7	8				
Amounts applied	Amounts applied	(1)	(7)	(8)				
Balance at September 30, 2023		\$ 1	\$ —	\$ 1				
Balance at March 31, 2024								
Balance at March 31, 2024								
Balance at March 31, 2024								

	Amounts				
(in millions)	December 31, 2022	Provisions	Applied	Change in Estimates	September 30, 2023
Connected Technology Solutions	\$ 3	\$ 15	\$ (6)	\$ 6	\$ 18
Essential Dental Solutions	4	23	(8)	(1)	18
Orthodontic and Implant Solutions	1	14	(4)	—	11
Wellspect Healthcare	—	4	(3)	—	1
All Other	—	10	(10)	(1)	(1)
Total	\$ 8	\$ 66	\$ (31)	\$ 4	\$ 47

REFINITIV 

Total derivative instruments designated as cash flow hedges	Total derivative instruments designated as cash flow hedges	\$	46	\$	46
---	---	----	----	----	----

Total derivative instruments designated as cash flow hedges

Total derivative instruments designated as cash flow hedges

Hedges of Net Investments	Hedges of Net Investments
----------------------------------	----------------------------------

Hedges of Net Investments

Hedges of Net Investments

Foreign exchange forward contracts
Foreign exchange forward contracts

Foreign exchange forward contracts	Foreign exchange forward contracts	\$	825	\$	85
------------------------------------	------------------------------------	----	-----	----	----

Cross currency basis swaps	Cross currency basis swaps		282		—
----------------------------	----------------------------	--	-----	--	---

Total derivative instruments designated as hedges of net investments	Total derivative instruments designated as hedges of net investments	\$	1,107	\$	85
--	--	----	-------	----	----

Fair Value Hedges	Fair Value Hedges
--------------------------	--------------------------

Fair Value Hedges

Interest rate swaps
Interest rate swaps

Interest rate swaps	Interest rate swaps	\$	250	\$	—
---------------------	---------------------	----	-----	----	---

Foreign exchange forward contracts	Foreign exchange forward contracts		50		50
------------------------------------	------------------------------------	--	----	--	----

Total derivative instruments designated as fair value hedges	Total derivative instruments designated as fair value hedges	\$	300	\$	50
--	--	----	-----	----	----

of net investments and the intrinsic value changes in these instruments are included in AOCI, recorded on AOCI, net of tax effects. The time-value component of the fair value of the derivative instrument is reported amortized on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign currency exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

On July 2, 2021, the Company entered into a cross currency basis swap totaling a notional amount of \$300 million which matures on June 3, 2030. The cross currency basis swap is designated as a hedge of net investments. This contract effectively converted a portion of the \$750 million bond coupon from 3.3% to 1.7%.

On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023 and the Company entered into additional foreign exchange contracts as individual contracts within the portfolio matured. As of September 30, 2023, the euro net investment hedge portfolio has an aggregate notional value of 160 million euro with maturity dates through September 2025.

On July 20, 2023, the Company entered into a Swiss franc foreign exchange forward contract designated as a net investment hedge. The foreign exchange forward contract had a notional amount of 600 million Swiss francs. This net investment hedge was settled in September 2023 which resulted in cash receipts totaling \$32 million. The Company subsequently entered into Swiss franc foreign exchange contracts designated as a net investment hedge with a total notional amount of 600 million Swiss francs. This portfolio of contracts has semi-annual maturity dates through July 2028.

Fair Value Hedges

Foreign Exchange Risk Management

The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in foreign currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in Other (income) expense, net in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other (income) expense, net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

Interest Rate Risk Management

On July 1, 2021 February 13, 2024, the Company entered into paid \$9 million to settle the variable interest rate swaps swap with a notional amount of \$250 \$100 million which effectively converted a portion was originally set to mature on June 1, 2026. This closure of the underlying fixed interest rate swap will result in a loss of 3.3% on \$8 million being amortized over the \$750 million remaining life of the Senior Notes due June 2030 to a variable interest rate. Of the \$250 million notional amount, \$100 million has a term of five-years maturing on June 1, 2026 and \$150 million has a term of nine years maturing on March 1, 2030. 2030.

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other (income) expense, net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

Gains and (losses) recorded in the Company's Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 were not significant.

Derivative Instrument Activity

The effect of derivative hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Income (Loss) Loss for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023 were as follows:

(in millions)	Three Months Ended September 30, 2023			Three Months Ended September 30, 2022		
	Cost of products sold	Interest expense, net	Other (income) expense, net	Cost of products sold	Interest expense, net	Other (income) expense, net
Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded	\$ 452	\$ 18	\$ (4)	\$ 439	\$ 14	\$ 9
(Gain) loss on Cash Flow Hedges reclassified from AOCI into income						

Foreign exchange forward contracts	\$	1	\$	—	\$	—	\$	(1)	\$	—	\$	—
Interest rate swaps		—		—		—		—		—		—
(Gain) loss on Hedges of Net Investment												
Cross currency basis swaps	\$	—	\$	(1)	\$	—	\$	—	\$	(2)	\$	—
Foreign exchange forward contracts		—		—		(5)		—		—		—
(Gain) loss on Fair Value Hedges:												
Interest rate swaps	\$	—	\$	3	\$	—	\$	—	\$	1	\$	—
Foreign exchange forward contracts		—		—		(1)		—		—		(13)

		Amount of Gain or (Loss) Recognized in AOCI		Amount of Gain or (Loss) Reclassified from AOCI into Income							
		Three Months Ended September 30,	Consolidated Statements of Operations	Three Months Ended September 30,	Consolidated Statements of Operations						
		2024	2023	2024	2023						
</											

AOCI into income

(Gain) loss on Cash Flow Hedges reclassified from AOCI into income

(Gain) loss on Cash Flow Hedges reclassified from AOCI into income

Foreign exchange forward contracts

Foreign exchange forward contracts

Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 1	\$ 3	Cost of products sold	\$ (1)	\$ 1
Interest rate swaps	Interest rate swaps	—	—	Interest expense, net	—	—

Hedges of Net Investments

(Gain) loss on Hedges of Net Investment

(Gain) loss on Hedges of Net Investment

(Gain) loss on Hedges of Net Investment

Cross currency basis swaps	Cross currency basis swaps	\$ 3	\$ 18	Interest expense, net	\$ —	\$ —
----------------------------	----------------------------	------	-------	-----------------------	------	------

Cross currency basis swaps

Cross currency basis swaps

Foreign exchange forward contracts	Foreign exchange forward contracts	29	11	Other expense (income), net	—	—
------------------------------------	------------------------------------	----	----	-----------------------------	---	---

Fair Value Hedges

(Gain) loss on Fair Value Hedges:

(Gain) loss on Fair Value Hedges:

(Gain) loss on Fair Value Hedges:

Interest rate swaps

Interest rate swaps

Interest rate swaps	Interest rate swaps	\$ —	\$ —	Interest expense, net	\$ —	\$ —
Foreign exchange	Foreign exchange	1	(1)	Other expense	—	—

forward contracts	forward contracts	(income), net
-------------------	-------------------	---------------

(Gain) loss on
Derivative
Instruments not
Designated as
Hedges
(Gain) loss on
Derivative
Instruments not
Designated as
Hedges
(Gain) loss on
Derivative
Instruments not
Designated as
Hedges
Foreign exchange
forward contracts
Foreign exchange
forward contracts
Foreign exchange
forward contracts

(in millions)	Nine Months Ended September 30, 2023			Nine Months Ended September 30, 2022		
	Cost of products sold	Interest expense, net	Other expense (income), net	Cost of products sold	Interest expense, net	Other expense (income), net
Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded	\$ 1,389	\$ 58	\$ 16	\$ 1,329	\$ 41	\$ 20
(Gain) loss on Cash Flow Hedges reclassified from AOCI into income						
Foreign exchange forward contracts	\$ 1	\$ —	\$ —	\$ (3)	\$ —	\$ —
Interest rate swaps	—	2	—	—	2	—
(Gain) loss on Hedges of Net Investment						
Cross currency basis swaps	\$ —	\$ (3)	\$ —	\$ —	\$ (4)	\$ —
Foreign exchange forward contracts	—	—	(6)	—	—	(1)
(Gain) loss on Fair Value Hedges:						
Interest rate swaps	\$ —	\$ 8	\$ —	\$ —	\$ —	\$ —
Foreign exchange forward contracts	—	—	(4)	—	—	(37)

	Amount of Gain or (Loss) Recognized in AOCI		Amount of Gain or (Loss) Reclassified from AOCI into Income
	Nine Months Ended September 30,	Consolidated Statements of Operations Location	Nine Months Ended September 30,

		Amount of Gain or (Loss) Recognized in AOCI						Amount of Gain or (Loss) Recognized in AOCI						Amount of Gain or (Loss) Recognized in AOCI						Amount of Gain or (Loss) Reclassified from AOCI into Income					
		Three Months Ended						Three Months Ended						Three Months Ended											
(in millions)	(in millions)	2023	2022	Consolidated Statements of Operations Location	2023	2022	(in millions)	2024	2023	2024	2023	Consolidated Statements of Operations Location	2024	2023	Consolidated Statements of Operations Location	2024	2023	Consolidated Statements of Operations Location							
Cash Flow Hedges	Cash Flow Hedges																								
Cash Flow Hedges																									
Cash Flow Hedges																									
Foreign exchange forward contracts																									
Foreign exchange forward contracts																									
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ —	\$ 3	Cost of products sold	\$ (1)	\$ 3																			
Interest rate swaps	Interest rate swaps	—	—	Interest expense, net	(2)	(2)																			
Hedges of Net Investments	Hedges of Net Investments																								
Hedges of Net Investments																									
Hedges of Net Investments																									
Cross currency basis swaps	Cross currency basis swaps	\$ (6)	\$ 47	Interest expense, net	\$ —	\$ —																			
Cross currency basis swaps																									
Cross currency basis swaps																									
Foreign exchange forward contracts																									
Foreign exchange forward contracts																									
Foreign exchange forward contracts																									

Fair Value Hedges						
Fair Value Hedges						
Fair Value Hedges						
Foreign exchange forward contracts						
Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts	26	24	Other expense (income), net	—	—
Fair Value Hedges						
Interest rate swaps						
		\$ —	\$ —	Interest expense, net	\$ —	\$ —
Foreign exchange forward contracts						
		2	(2)	Other expense (income), net	—	—

Consolidated Balance Sheets Location of Derivative Fair Values

The fair value and the location financial statement presentation of the Company's derivatives in the Consolidated Balance Sheets were as follows:										
September 30, 2023										
March 31, 2024							March 31, 2024			
		Prepaid Expenses and Other								
		Current	Noncurrent	Accrued	Noncurrent	(in	Prepaid Expenses and Other	Other Noncurrent	Accrued	Other Noncurrent
(in millions)	(in millions)	Assets	Assets	Liabilities	Liabilities	millions)	Current Assets	Assets	Liabilities	Liabilities
Designated as Hedges:	Designated as Hedges:									
Designated as Hedges:										
Designated as Hedges:										
Foreign exchange forward contracts										
Foreign exchange forward contracts										
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 27	\$ 1	\$ 5	\$ 4					
Interest rate swaps	Interest rate swaps	—	—	12	25					
Cross currency basis swaps	Cross currency basis swaps	3	17	—	—					
Total	Total	\$ 30	\$ 18	\$ 17	\$ 29					
Not Designated as Hedges:	Not Designated as Hedges:									
Not Designated as Hedges:										
Not Designated as Hedges:										

Foreign exchange forward contracts						
Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 8	\$ —	\$ 3	\$ —	
Total	Total	\$ 8	\$ —	\$ 3	\$ —	
December 31, 2022						
December 31, 2023						
December 31, 2023						
December 31, 2023						
	Prepaid Expenses and Other Current Assets	Other Noncurrent Assets	Accrued Liabilities	Other Noncurrent Liabilities		
(in millions)	(in millions)					
Designated as Hedges:						
Designated as Hedges:						
Designated as Hedges:						
Foreign exchange forward contracts						
Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 32	\$ 3	\$ 5	\$ 2	
Interest rate swaps	Interest rate swaps	—	—	9	25	
Cross currency basis swaps	Cross currency basis swaps	4	22	—	—	
Total	Total	\$ 36	\$ 25	\$ 14	\$ 27	
Not Designated as Hedges:						
Not Designated as Hedges:						
Foreign exchange forward contracts						
Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 3	\$ —	\$ 5	\$ —	
Total	Total	\$ 3	\$ —	\$ 5	\$ —	

Balance Sheet Offsetting

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2023 March 31, 2024 were as follows:

39/76

REFINITIV 

Interest rate swaps							
Interest rate swaps	Interest rate swaps	37	—	37	(7)	—	30
Total liabilities	Total liabilities	\$ 49	\$ —	\$ 49	\$ (13)	\$ —	\$ 36
Total liabilities							
Total liabilities							

Offsetting of financial assets and liabilities under netting arrangements at **December 31, 2022** **December 31, 2023** were as follows:

Gross Amounts Not Offset in the Consolidated Balance Sheets							
Gross Amounts Not Offset in the Consolidated Balance Sheets							
Gross Amounts Not Offset in the Consolidated Balance Sheets							
Gross Amounts Not Offset in the Consolidated Balance Sheets							
(in millions)							
(in millions)							
		Gross Amount Recognized	Net Amounts Presented in the Consolidated Balance Sheets				
(in millions)	(in millions)	Gross Amounts Recognized	Balance Sheets	Balance Sheets	Financial Instruments	Cash Collateral Received/Pledged	Net Amount
Assets	Assets						
Assets	Assets						
Assets	Assets						
Foreign exchange forward contracts	Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts						
Foreign exchange forward contracts	Foreign exchange forward contracts	\$ 38	\$ —	\$ 38	\$ (7)	\$ —	\$ 31
Cross currency basis swaps	Cross currency basis swaps						
Cross currency basis swaps	Cross currency basis swaps						
Cross currency basis swaps	Cross currency basis swaps	26	—	26	(12)	—	14
Total assets	Total assets	\$ 64	\$ —	\$ 64	\$ (19)	\$ —	\$ 45
Liabilities	Liabilities						
Liabilities	Liabilities						
Liabilities	Liabilities						
Foreign exchange forward contracts	Foreign exchange forward contracts						

Foreign exchange forward contracts							
Foreign exchange forward contracts	Foreign exchange forward contracts	\$	12	\$	—	\$	12
						\$	(10)
						\$	—
						\$	2
Interest rate swaps							
Interest rate swaps							
Interest rate swaps	Interest rate swaps		34		—		34
							(9)
							—
							25
Total liabilities	Total liabilities	\$	46	\$	—	\$	46
							(19)
							—
							27
Total liabilities							
Total liabilities							

NOTE 10 – FAIR VALUE MEASUREMENT

The estimated fair value and carrying value values of the Company's total debt was \$1,817 million were \$1,972 million and \$1,989 million \$2,090 million, respectively, at September 30, 2023 March 31, 2024. At December 31, 2022 December 31, 2023, the estimated fair value and carrying value values were \$1,769 million \$2,018 million and \$1,944 million \$2,118 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company's public debt or is determined by discounting future cash flows using interest rates available at September 30, 2023 March 31, 2024 and December 31, 2022 to December 31, 2023 and interest rates for companies with similar credit ratings for issues issuances with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.

Assets and liabilities measured at fair value on a recurring basis

The Company's financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:

		March 31, 2024				March 31, 2024				March 31, 2024			
(in millions)		(in millions)				(in millions)				(in millions)			
		Total				Level 1				Level 2			
Assets													
Assets													
Assets													
		September 30, 2023											
		Level Level Level											
(in millions)		Total	1	2	3	Total	1	2	3	Total	1	2	3
Cross currency basis swaps													
Assets													
Cross currency basis swaps													
Cross currency basis swaps	Cross currency basis swaps	\$20	\$ —	\$ 20	\$ —								
Foreign exchange forward contracts	Foreign exchange forward contracts	36	—	36	—								
Total assets	Total assets	\$56	\$ —	\$ 56	\$ —								
Total assets													
Total assets													
Liabilities													
Liabilities													
Liabilities													
Interest rate swaps													
Interest rate swaps													

Interest rate swaps	Interest rate swaps	\$37	\$ —	\$ 37	\$ —
Foreign exchange forward contracts	Foreign exchange forward contracts	12	—	12	—
Foreign exchange forward contracts					
Foreign exchange forward contracts					
Contingent considerations on acquisitions					
Contingent considerations on acquisitions					
Contingent considerations on acquisitions	Contingent considerations on acquisitions	4	—	—	4
Total liabilities	Total liabilities	\$53	\$ —	\$ 49	\$ 4
December 31, 2023					
December 31, 2023					
December 31, 2023					
(in millions)	(in millions)	TotalLevel 1Level 2Level 3			
Assets					
Assets					
Assets					
	December 31, 2022				
	LevelLevelLevel				
(in millions)	Total123				
Assets					
Cross currency basis swaps					
Cross currency basis swaps					
Cross currency basis swaps	Cross currency basis swaps	\$26	\$ —	\$ 26	\$ —
Foreign exchange forward contracts	Foreign exchange forward contracts	38	—	38	—
Total assets	Total assets	\$64	\$ —	\$ 64	\$ —
Total assets					
Total assets					
Liabilities	Liabilities				
Liabilities					
Liabilities					
Interest rate swaps					
Interest rate swaps					
Interest rate swaps	Interest rate swaps	\$34	\$ —	\$ 34	\$ —
Foreign exchange forward contracts	Foreign exchange forward contracts	12	—	12	—

Foreign exchange forward contracts					
Foreign exchange forward contracts					
Contingent considerations on acquisitions					
Contingent considerations on acquisitions					
Contingent considerations on acquisitions	Contingent considerations on acquisitions	4	—	—	4
Total liabilities	Total liabilities	\$50	\$ —	\$ 46	\$ 4
Total liabilities					
Total liabilities					

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. The Company utilizes interest rate swaps and foreign exchange forward contracts that are considered cash flow **hedges or fair value** hedges. In addition, **at times**, the Company **at times** employs certain cross currency **basis interest rate** swaps and forward exchange **forward** contracts that are considered hedges of net investment in foreign operations.

There **have been were** no transfers between fair value measurement levels during the **nine three** months ended **September 30, 2023** **March 31, 2024**.

NOTE 11 – INCOME TAXES

The effective tax rate for the three months ended **September 30, 2023**, **March 31, 2024** and **2022** **2023** was (6.3%) **44.9%** and **13.2%**, respectively. The effective tax rate for the **nine months ended September 30, 2023**, and **2022** was **12.1%** and **12.1%** **18.4%**, respectively. The quarter to date **decrease increase** in the effective tax rate is due to **the goodwill** an increase in valuation allowance and **intangible impairments**, a shift in geographical mix of earnings towards jurisdictions with higher statutory tax rates.

The Company performed an assessment to evaluate the new global minimum tax developed by the Organisation for Economic Co-operation and Development ("Pillar Two"), which involved analyzing the tax laws in each jurisdiction in which the Company operates and modeling the implications with the Pillar Two framework. The impact of Pillar Two on the Company was not significant. The Company included the impact of the top-up tax under the Income Inclusion Rule for those jurisdictions in which the Company failed the transitional safe harbor requirement in its full year 2024 effective tax rate.

NOTE 12 – FINANCING ARRANGEMENTS

The Company has a five-year senior unsecured multi-currency revolving facility, for an aggregate principal amount of \$700 million, that expires on May 12, 2028. The Company also has a \$500 million commercial paper program. The \$700 million multi-currency revolving credit facility serves as a back-up to the commercial paper facility, resulting in an aggregate of \$700 million as the total available credit under the commercial paper facility and the multi-currency revolving credit facility. The Company had outstanding borrowings of \$249 million and \$225 million under the commercial paper facility at March 31, 2024 and December 31, 2023, respectively, and no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to \$43 million in uncommitted short-term financing available under lines of credit from various financial institutions, which is reduced by other outstanding short-term borrowings of \$19 million. At **September 30, 2023** **March 31, 2024**, the weighted-average interest rate for short-term debt was 5.6%.

At **March 31, 2024**, the Company had **\$562 million** **\$475 million** of **borrowing borrowings** available under lines of credit, including lines available under its short-term arrangements and revolving credit facility.

On May 12, 2023, the Company entered into the five-year senior unsecured multicurrency revolving facility, for an aggregate principal amount of \$700 million that expires on May 12, 2028. The Facility replaced the \$700 million five-year senior unsecured multicurrency revolving facility that was scheduled to expire on July 26, 2024. The Company also has a \$500 million commercial paper program. The \$700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is \$700 million. The Company had outstanding borrowings of \$165 million and \$95 million under the commercial paper facility at September 30, 2023 and December 31, 2022, respectively, and no outstanding borrowings under the multi-currency revolving credit facility.

The Company also has access to \$48 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings of \$21 million. At **September 30, 2023**, the weighted-average interest rate for short-term debt was 5.5%.

The Company's revolving credit facility, term loans, and senior notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. At **September 30, 2023** **March 31, 2024**, the Company was in compliance with all debt covenants.

Interest expense, net includes interest income of \$5 million and \$4 million for the three months ended **March 31, 2024** and **2023**, respectively, primarily relating to interest-bearing cash equivalents and customer financing for our direct-to-consumer aligner solutions.

NOTE 13 – GOODWILL AND INTANGIBLE ASSETS

The Company assesses both Company's policy is to assess goodwill and indefinite-lived intangible assets for impairment annually as of April 1, or with more frequently frequent assessments if events or changes in circumstances indicate the asset might be impaired.

On April 1, 2023, the Company realigned its reporting due to a change in organizational structure. Reporting units under the former structure were tested for impairment prior to the realignment, and no impairment was identified.

As a result of the realignment, the Company reallocated its goodwill to align its new reporting units which resulted from the change in its operating segments. Goodwill was reassigned to each of the new reporting units using a relative fair value approach. The Company assessed the goodwill of the new reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2023. Based on this test, it was determined that the fair values of its reporting units and indefinite-lived intangible assets more likely than not exceeded their carrying values, resulting in no impairment.

In the quarter three months ended September 30, 2023 March 31, 2024, the Company identified indicators of a more more likely than not not impairment related to its Connected Technology Solutions reporting unit, which comprises all of certain indefinite-lived imaging product trade names within the Connected Technology Solutions segment. The decline in fair value for this reporting unit of these indefinite-lived trade names was driven by adverse macroeconomic factors declines in volumes during the first quarter of 2024, which is due in part to a loss in market share from competitive pricing pressures, as a result of weakened demand, particularly well as unfavorable economic conditions in European markets, and increased discount rates. Since the second quarter, core underlying market interest rates, which serve as the basis for the discount rate assumptions in our impairment models, rose by approximately 110 basis points, certain markets. These factors contributed to reduced a reduction in forecasted revenues lower operating margins, and reduced expectations for future cash flows in the near term, particularly demand for products which are commonly financed by end customers and are therefore adversely impacted by an environment of higher interest rates. term. The higher inflationary environment has also impacted the discretionary spending behavior of our customers more generally, further reducing global demand for certain products in favor of lower cost options.

For the goodwill impairment test as of September 30, 2023, the fair value of the Connected Technology Solutions reporting unit was computed using a discounted cash flow model with inputs developed using both internal and market-based data. The discounted cash flow model uses ten-year forecasted cash flows plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. Significant assumptions used in the discounted cash flow model included, but were not limited to, discount rates of 11.5%, revenue growth rates (including perpetual growth rates), operating margin percentages, and net working capital changes of the reporting unit's business. As a result, the Company recorded a pre-tax goodwill impairment charge as of September 30, 2023 related to the Connected Technology Solutions reporting unit of \$291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment.

Based on quantitative and qualitative analyses performed for the other four reporting units, the Company believes there is no indication that the carrying value "more likely than not" exceeds the fair value in each case as of September 30, 2023; however, any further deterioration in key assumptions could result in impairment charges in the future. For the Company's reporting units that were not impaired, the Company applied a hypothetical sensitivity analysis by increasing the discount rate of these reporting units by 100 basis points. If discount rates were hypothetically increased by 100 basis points at September 30, 2023, the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was \$1,133 million at September 30, 2023.

Additionally, in conjunction with the goodwill impairment test in the quarter ended September 30, 2023, the Company tested the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment for impairment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment, and determined certain tradenames and trademarks were impaired. These indefinite-lived intangible assets trade names were evaluated for impairment using an income approach, specifically a relief from royalty method. Significant assumptions used in the relief from royalty method included, but were not limited to, a discount rates (ranging from 11.5% to 16.5%) rate of 11%, revenue growth rates (including perpetual growth rates), and royalty rates. As a result, the Company recorded an indefinite-lived intangible asset impairment charges charge of \$14 \$6 million and \$2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023 March 31, 2024. The impairment charge was primarily driven by macroeconomic factors such as weakened demand, higher cost remaining carrying value of capital, and cost inflation, which are contributing to reduced forecasted revenues. These charges were recorded in Goodwill and this intangible asset impairment in the Consolidated Statements group was \$22 million as of Operations. March 31, 2024. As the fair value of these indefinite-lived intangible assets approximate approximates carrying value, as of September 30, 2023, any further decline in key assumptions could result in additional impairment in future periods. the future.

Based on the interim quantitative and qualitative assessments performed on for the Company's other indefinite-lived intangible assets related to the businesses in the other and reporting units, the Company believes there is no indication does not believe that the carrying value "more more likely than not" not exceeds the fair value of these indefinite-lived intangible assets in each case as of September 30, 2023 March 31, 2024; however, therefore, the Company did not identify any indicators of a more likely than not impairment related to its goodwill or intangible assets, other than as noted above. However, any further deterioration in key assumptions could result in impairment charges in the future.

For the Company's indefinite-lived intangible assets that were not impaired, the The Company performed applied a hypothetical sensitivity analysis by increasing the discount rate used to value these indefinite-lived intangible assets and reporting units by 100 basis points. Under this sensitivity, certain indefinite-lived intangibles As of March 31, 2024, the estimated fair value of the Implants & Prosthetics reporting unit within the Connected Technology Orthodontic and Implant Solutions and Essential Dental Solutions segments segment exceeded its carrying value by less than 15%. If discount rates were hypothetically increased by 100 basis points, this reporting unit would have a an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was \$1,148 million as of March 31, 2024.

The carrying value fair values of these certain indefinite-lived intangible assets within the Connected Technology Solutions and Orthodontic and Implants Solutions segments continued to approximate carrying values as of March 31, 2024. Any further decline in key assumptions could result in additional impairments in future periods. The carrying values of these assets within the aforementioned segments was \$27 were \$182 million and \$7 \$23 million, respectively, at September 30, 2023 as of March 31, 2024.

Any deviation There is a risk of future impairment charges if there is a decline in the fair value of the reporting units or indefinite-lived intangible assets as a result of, among other things, actual financial results compared to the forecasted financial results or that are lower than forecasts, an adverse change in valuation assumptions, used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge, assets. There can be no assurance that the Company's future asset impairment testing will not result in a material charge to earnings.

Third Quarter 2022 Impairment

In the third quarter of 2022, the Company identified indicators of a more likely than not impairment related to its former Digital Dental Group and Equipment & Instruments reporting units and indefinite-lived intangible assets, included within the former Technologies & Equipment segment, and indicators of a more likely than not impairment related to its indefinite-lived intangible assets for the former Consumables reporting unit within the former Consumables segment. The Company recorded a pre-tax goodwill impairment charge related to its former Digital Dental Group and Equipment & Instruments reporting units within the former Technologies & Equipment segment of \$1,100 million and \$87 million, respectively, and an indefinite-lived intangible asset impairment charge of \$66 million and \$26 million for the former Digital Dental Group and Equipment & Instruments reporting units, respectively, within the former Technologies & Equipment segment and a \$2 million impairment charge for the former Consumables reporting unit within the former Consumables segment for the three months ended September 30, 2022.

A reconciliation of changes in the Company's goodwill by reportable segment were as follows:

(in millions)	Connected							Total
	Technologies & Equipment	Consumables	Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare		
Balance at December 31, 2022								
Goodwill	\$ 5,902	\$ 866	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 6,768
Accumulated impairment losses	(4,080)	—	—	—	—	—	—	(4,080)
Goodwill, net December 31, 2022	\$ 1,822	\$ 866	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 2,688
Translation	9	4	—	—	—	—	—	13
Balance at March 31, 2023								
Goodwill	\$ 5,911	\$ 870	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 6,781
Accumulated impairment losses	(4,080)	—	—	—	—	—	—	(4,080)
Goodwill, net March 31, 2023	\$ 1,831	\$ 870	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 2,701
Realignment of goodwill	\$ (1,831)	\$ (870)	\$ 293	\$ 835	\$ 1,303	\$ 270	\$ —	\$ —
Translation	—	—	—	1	(5)	6	—	2
Goodwill, net June 30, 2023	\$ —	\$ —	\$ 293	\$ 836	\$ 1,298	\$ 276	\$ —	\$ 2,703
Impairment	—	—	(291)	—	—	—	—	(291)
Translation	—	—	(2)	(7)	(19)	(10)	—	(38)
Balance at September 30, 2023								
Goodwill	\$ —	\$ —	\$ 291	\$ 829	\$ 1,279	\$ 266	\$ —	\$ 2,665
Accumulated impairment losses	—	—	(291)	—	—	—	—	(291)
Goodwill, net September 30, 2023	\$ —	\$ —	\$ —	\$ 829	\$ 1,279	\$ 266	\$ —	\$ 2,374

(in millions)	Connected Technology Solutions	Essential Dental Solutions	Orthodontic and Implant Solutions	Wellspect Healthcare	Total
Balance at December 31, 2023					
Goodwill	\$ 291	\$ 840	\$ 1,323	\$ 275	\$ 2,729
Accumulated impairment losses ^(a)	(291)	—	—	—	(291)
Goodwill, net at December 31, 2023	—	840	1,323	275	2,438
Impairment	—	—	—	—	—
Foreign Currency Translation	—	(5)	(30)	(3)	(38)

Balance at March 31, 2024					
Goodwill		291		835	
Accumulated impairment losses		(291)		—	
Goodwill, net at March 31, 2024	\$	—	\$	835	\$
				1,293	
				—	
				—	
				272	
				—	
				2,400	

(a) The Company realigned segments in 2023, and at that time, there was an accumulated impairment loss that was not allocated to the new segments.

Identifiable definite-lived and indefinite-lived intangible assets were as follows:

September 30, 2023								December 31, 2022									
March 31, 2024								March 31, 2024								December 31, 2023	
		Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	(in millions)	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount			
(in millions)	(in millions)																
Developed technology and patents	Developed technology and patents	\$ 1,648	\$ (939)	\$ 709	\$ 1,658	\$ (848)	\$ 810										
Tradenames and trademarks		271	(98)	173	273	(96)	177										
Developed technology and patents																	
Developed technology and patents																	
Trade names and trademarks																	
Licensing agreements	Licensing agreements	29	(27)	2	30	(26)	4										
Customer relationships	Customer relationships	1,038	(642)	396	1,057	(600)	457										
Total definite-lived	Total definite-lived	\$ 2,986	\$ (1,706)	\$ 1,280	\$ 3,018	\$ (1,570)	\$ 1,448										
Indefinite-lived tradenames and trademarks		\$ 426	\$ —	\$ 426	\$ 450	\$ —	\$ 450										
Indefinite-lived trade names and trademarks																	
Indefinite-lived trade names and trademarks																	
Indefinite-lived trade names and trademarks																	
In-process R&D (a)	In-process R&D (a)	5	—	5	5	—	5										
Total indefinite-lived	Total indefinite-lived	\$ 431	\$ —	\$ 431	\$ 455	\$ —	\$ 455										
Total identifiable intangible assets	Total identifiable intangible assets	\$ 3,417	\$ (1,706)	\$ 1,711	\$ 3,473	\$ (1,570)	\$ 1,903										
Total identifiable intangible assets																	
Total identifiable intangible assets																	

During the second quarter of 2021, the Company purchased certain developed technology rights for an initial payment of \$3 million. The purchase consideration also includes minimum guaranteed contingent payments of \$17 million to be made upon reaching certain regulatory and commercial milestones. The contingent payments are not yet considered probable of payment as of September 30, 2023 March 31, 2024.

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Contingencies

On January 25, 2018, Futuredontics, Inc. December 19, 2018, a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Caethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys' General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys' General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato). The court in Cato approved the settlement in that case, the settlement payment has been made, and the court dismissed the lawsuit. The parties have also reached a settlement in the Olivares and Holt class action, which is immaterial to the financial statements of the Company. The final settlement amount has been approved by the Court and was paid by the Company in the first quarter of 2023.

On June 7, 2018, and August 9, 2018, two putative class action suits were filed and later consolidated, in the Supreme U.S. District Court of for the State Eastern District of New York County of New York claiming against the Company and certain individual defendants. The plaintiff claims that the Company, and certain individual defendants, violated U.S. securities laws (the "State Court Action") by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. ("Sirona" ("Sirona")) with DENTSPLY International Inc. (the "Merger" ("Merger")). The amended complaint alleges and that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company's Company's products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company's stock in the Merger. On September 26, 2019, the Court granted the Company's motion to dismiss all claims and a judgment dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs' post-judgment motion to vacate or modify the judgment and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the post-judgment motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court's decision dismissing the action. The plaintiffs' appeals and the Company's cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision.

On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants. The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company's stock during the period from February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021, with briefing on the motion fully submitted on May 21, 2021. The Company's motion to dismiss was denied in a ruling by the Court on March 29, 2023 and the Company's answer to the second amended complaint was filed on May 12, 2023. On September 29, 2023, the plaintiff filed a motion for class certification. The Company opposition to the plaintiff's motion for class certification is due December 21, 2023 was filed on February 8, 2024, with briefing on the plaintiff's motion to be fully completed by February 23, 2024 May 10, 2024.

On June 2, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees' & Sanitation Employees' Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371, (S.D. Ohio), and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the U.S. District Court for the Southern District of New York captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the "Securities Litigation"). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company's former Chief Executive Officer, and Mr. Jorge Gomez, the Company's former Chief Financial Officer, violated U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognized revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the Southern District of New York (the "Court" ("Court")). On June 1, 2023, the Court consolidated the two separate actions under case No. 1:22-cv-06339 and appointed the City of Birmingham Retirement and Relief System, the El Paso Firemen & Policemen's Pension Fund, and the Wayne County Employees' Retirement System as Lead Plaintiffs for the putative class. Lead Plaintiffs filed an amended class action complaint on July 28, 2023 (the "Amended Complaint" ("Amended Complaint")). In addition to asserting the same claims against the Company, Mr. Casey, and Mr. Gomez, the Amended Complaint added the Company's former Chief Accounting Officer, Mr. Ranjit S. Chadha, as a defendant (collectively, "Defendants"). On October 10, 2023, Defendants filed a motion to dismiss the Amended Complaint. Lead Plaintiffs' opposition to Defendants' motion to dismiss is due by was filed on December 8, 2023, and Defendants' reply is due was filed on January 8, 2024. The motion to dismiss was granted as to Mr. Chadha and granted in part and denied in part as to the Company, Mr. Casey, and Mr. Gomez in a ruling by January 8, 2024 the Court on May 1, 2024.

In addition to the Securities Litigation, as previously disclosed, the Company voluntarily contacted the SEC following the Company's announcement on May 10, 2022 of the Audit and Finance Committee's internal investigation. The Company continues to cooperate with the SEC regarding this matter.

Separately, on July 13, 2023, Dentsply Sirona stockholder George Presura filed a shareholder derivative suit in the Delaware Court of Chancery captioned George Presura, Derivatively on Behalf of Nominal Defendant Dentsply Sirona Inc. v. Donald M. Casey Jr. et al. and Dentsply Sirona, Inc., No. 2023-0708-NAC (the "Derivative" ("Presura Derivative Litigation")). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Securities Litigation, and it alleges

that during the period from June 9, 2021 through July 13, 2023, various of the defendants breached fiduciary duties, committed corporate waste, and misappropriated information to conduct insider trading by making materially false and misleading statements or omissions regarding the Company's recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels. On August 4, 2023, the Delaware Court of Chancery stayed the **Presura** Derivative Litigation until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation.

Additionally, on March 26, 2024, Dentsply Sirona stockholder Calvin Snee filed a shareholder derivative suit in the Delaware Court of Chancery captioned Calvin Snee, derivatively on behalf of Dentsply Sirona Inc. v. Donald M. Casey Jr., et al. and Dentsply Sirona Inc, No. 2024-0308 (the "Snee Derivative Litigation"). The complaint, filed derivatively on behalf of the Company, asserts claims against current and former members of the Company's Board of Directors and current and former executive officers, including Messrs. Casey and Gomez. The derivative complaint in this case contains allegations similar to those in the Presura Derivative Litigation and the Securities Litigation, and it alleges that beginning in 2021, various of the defendants breached fiduciary duties, misappropriated information to conduct insider trading, and were unjustly enriched by making materially false and misleading statements or omissions regarding the Company's recognition of revenue tied to distributor rebate and incentive programs and distributor inventory levels.

On April 30, 2024, the Company and the plaintiffs in the Presura Derivative Litigation and Snee Derivative Litigation, filed a joint request in the Delaware Court of Chancery to consolidate and stay both cases until the earlier of public announcement of a settlement of the Securities Litigation or resolution of the pending motion to dismiss in the Securities Litigation. The request is pending.

On March 21, 2023, Mr. Carlo Gobetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l. ("**DSI**" ("**DSI**"), Italy, a wholly owned subsidiary of the Company, seeking a total of €28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the "SPA"), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now Dentsply Sirona Italia S.r.l.). In connection with the closing of that transaction, SIRONA Dental Systems GmbH paid an amount equal to €7 million into an escrow account (the "Escrow Account"). The proceeds of the Escrow Account were to be released to Mr. Gobetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. Mr. Gobetti claims that he is entitled to receive the €7 million outstanding balance of the purchase price under the SPA, plus €21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. On May 15, 2023, DSI filed its initial statement of **Defense** defense denying that Mr. Gobetti and the other sellers were entitled to receive the funds deposited in the Escrow Account and further disputing the allegations. Following the constitution of the arbitral tribunal, **the first hearing was** hearings were held on September 13, 2023 and January 19, 2024, to illustrate and discuss their respective positions. The parties were also permitted to further develop their arguments in one additional round of defensive briefs. On January 29, 2024, the parties filed a statement setting out their final pleadings. The Arbitral Court eventually decided that the procedural issues raised by DSI (jurisdiction, capacity to be sued) will be considered together with the merits and granted the parties final deadlines to file their respective final briefs (March 29, 2024) and replies (April 15, 2024). Such filings have been completed and the next step is the final hearing **is** for discussion scheduled for **January 19, 2024** May 8, 2024.

Except as noted above, no specific amounts of damages have been alleged in these lawsuits. The Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. The Company intends to defend these lawsuits vigorously, but there can be no assurance that the Company will be successful in any defense. If any of the lawsuits are decided adversely, the Company may be liable for significant damages directly or under **our its** indemnification obligations, which could adversely affect **our the Company's** business, results of operations and cash flows. At this stage, the Company is unable to assess whether any material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.

The Internal Revenue Service ("IRS") **conducted an examination of the U.S. federal income tax returns for tax years 2012 through 2014.** In February 2019, the IRS issued to the Company a "30-day letter" and a Revenue Agent's Report ("RAR"), relating to the Company's worthless stock deduction in 2013 in the amount of \$546 million. The RAR disallows the deduction and, after adjusting the Company's net operating loss carryforward, asserts that the Company is entitled to a refund of \$5 million for 2012, has no tax liability for 2013, and owes a deficiency of \$17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company's 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Independent Office of Appeals (the "Appeals Office") in October 2020, and in November 2020 submitted a supplemental response to questions raised by the Appeals Office. During the first quarter of 2023, after an extended review by the Appeals Office, the Company received a notice from the IRS, allowing the Company's worthless stock deduction for tax year 2013. As a result, the Company received a refund of \$5 million for tax year 2012 with no further adjustments to the 2013 or 2014 tax return.

IRS is conducting an examination of **our the Company's** U.S. federal income tax returns for the tax years 2015 **through and** 2016. **In April 2023, the** The Company received a Notice of Proposed Adjustment in April 2023 and a Revenue Agent Report in January 2024 from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax liability for the internal reorganization, if sustained, the proposed adjustment would result in the Company owing additional federal income taxes on a distribution of \$451 million **as a result of related** to a stock redemption that occurred after the internal reorganization was completed in 2016. **We believe** The amount of additional federal income taxes due for 2016 is approximately \$2 million, excluding interest. The proposed adjustment, if sustained, would also result in a loss of foreign tax credits carried forward to later tax years. The Company believes that **we it** accurately reported the federal income tax consequences of the internal restructuring and stock redemption in **our its** tax returns and **will submit in April 2024, submitted** an administrative protest with the IRS Independent Office of Appeals contesting the examination team's proposed adjustments if the issue is not resolved with the IRS examination team. **We intend adjustments.** The Company intends to vigorously defend **our its** reported positions, positions and believes that it is more likely than not that its positions will be sustained. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. **If determined adversely, the dispute could have a material adverse effect on the consolidated results of operations, financial position, and liquidity of the Company.**

The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company's products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory, damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company's experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company's business, financial condition, results of operations, or liquidity.

While the Company maintains general, product, property, workers' compensation, automobile, cargo, aviation, crime, fiduciary and directors' and officers' liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

Commitments

Purchase Commitments

The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At September 30, 2023 March 31, 2024, non-cancelable purchase commitments are were as follows:

(in millions)	(in millions)	
2023		\$ 58
2024		
2024		
2024	2024	174
2025	2025	56
2026	2026	57
2027	2027	1
2028		
Thereafter	Thereafter	—
Total	Total	\$ 346

The above information should be read in conjunction with Part II, Item 7 "Contractual Obligations" and Part II, Item 8, Note 22, 21, Commitments and Contingencies, in our 2022 2023 Form 10-K/A, 10-K.

The table above includes commitments under our agreement with a cloud services provider supporting our digital platform which requires us to make minimum purchases totaling \$98 million through 2028.

Off-Balance Sheet Arrangements

As of September 30, 2023 March 31, 2024, we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above.

Indemnification

In the normal course of business to facilitate the sale of our products and services, we indemnify certain parties; parties, including customers, vendors, lessors, service providers, and other parties others, with respect to certain matters, including, but not limited to, services to be provided by or for us, and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.

It is not possible to make a reasonable estimate of the maximum potential amount of indemnification under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material effect on our results of operations, cash flows or financial position. As of September 30, 2023 March 31, 2024, we did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period.

DENTSPLY SIRONA Inc. and Subsidiaries

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

Information included in or incorporated by reference in this Form 10-Q, and other filings with the SEC and the Company's press releases or other public statements, contains or may contain forward-looking statements. Please refer to the discussion under the header "Forward-Looking Statements and Associated Risks" in the forepart of this Form 10-Q.

Company Profile

DENTSPLY SIRONA Inc. is the world's largest manufacturer of professional dental products and technologies, with a 136-year 137-year history of innovation and service to the dental industry and patients worldwide, a vision of improving oral health and continence care globally. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions, offering including technologically advanced dental equipment supported by cloud software solutions as well as dental products and healthcare consumable products in urology and orthodontic and implant products enterology under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. Dentsply Sirona's products provide innovative, high-quality, and effective solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona's worldwide headquarters is located in Charlotte, North Carolina. The Company's shares of common stock are listed in the United States on the Nasdaq stock market under the symbol XRAY.

Material Weaknesses in Internal Control Over Financial Reporting

As previously disclosed, management determined there were material weaknesses in the Company's internal control over financial reporting as of December 31, 2022, which have not been remediated as of September 30, 2023. For more information about the identified material weaknesses in internal control over financial reporting and the Company's remedial actions, please see Part I, Item 4 Controls and Procedures of this Form 10-Q.

BUSINESS

Effective April 1, 2023, and The Company operates in conjunction with our updated strategic operating realignment, the Company's reporting segment structure changed from Technology & Equipment and Consumables to (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare.

A description of the products and services provided within each of the Company's four reportable segments is provided as described below. Refer also to Note 6, Segment Information, in Part I, Item 1 of this Form 10-Q for more information.

Connected Technology Solutions

This segment is responsible for includes the design, manufacture, and sales of the Company's dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories. Dental CAD/CAM technologies are products designed for dental offices to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform.

Essential Dental Solutions

This segment is responsible for includes the design, development, manufacture, and sales of the Company's value-added endodontic, restorative, and preventive consumables consumable products and small equipment used in dental offices for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the preparation creation of dental appliances.

Orthodontic and Implant Solutions

This segment is responsible for includes the design, manufacture, and sales of the Company's various digital implant systems and innovative dental implant products, digital dentures and dentist dental professional directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.

Wellspect Healthcare

This segment is responsible for includes the design, manufacture, and sales of the Company's innovative continence care solutions.

solutions for both urinary and bowel management. This category consists mainly of urology catheters and other healthcare-related consumable products.

The impact of the recent Israel-Hamas war

The recent terrorist attacks by Hamas militants crossing the border from Gaza to Israel in October 2023 and the subsequent military response by the Israeli government in Gaza has resulted in significant unrest and uncertainty within that region, including region. In April 2024, the state of Israel was also a target of a coordinated missile and drone direct attack launched by the Republic of Iran. These events have heightened the possibility that escalating violence and involvement of other terrorist groups from neighboring countries or foreign powers in the region may further impact our employees and operations.

The Company's operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one in southern Israel, which together employ approximately 300 associates. These facilities remain open and continue to operate. We may, however, determine decide to discontinue production at these facilities for the safety of our employees, or we could face future production slowdowns or interruptions at either location due to the impacts of the war, including personnel absences as a number of our employees have been called to active military duty, or due to other resource constraints such as the inability to source materials for production.

For the quarter three months ended September 30, 2023 March 31, 2024, net sales of products produced at these sites comprise comprised approximately 3% 4% of our consolidated net sales and 18% 13% of the net sales attributed to our Orthodontics of the Orthodontic and Implants Implant Solutions segment. Net assets within Israel total \$193 million \$192 million as of September 30, 2023 March 31, 2024, consisting primarily of acquired technology, cash, inventory, and property, plant and equipment associated with our operations in country. While Overall, the Company's operations in Israel have not been materially impacted by the conflict, had no impact on results for the quarter ended September 30, 2023, and consequently, the Company has initiatives underway not recorded any allowance for doubtful accounts, inventory reserves, or asset impairments through the three months ended March 31, 2024. The Company continues to move inventory to locations in southern Europe monitor developments and prepare contingency plans to limit the potential disruption to our implants product sales and operations for the fourth quarter of 2023 and fiscal year 2024. its operations.

Additionally, the Company sells we sell products from across our business portfolio to distributors of dental products and direct to dental practices within Israel and its neighboring countries which may face reduced patient traffic and demand for our products in the near term. Net sales for products sold to our customers in Israel comprise less than comprised approximately 1% of our consolidated net sales for the quarter three months ended September 30, 2023 March 31, 2024.

While Israel does not constitute a material portion of our business, a significant escalation or expansion of the conflict's conflict's current scope and economic disruption could result in loss of sales and market position, disrupt our supply chain, broaden inflationary costs including energy prices, and have a material adverse effect on our results of operations, including impairment of the net assets in Israel or the goodwill associated our with the Implants & Prosthetics reporting unit.

The impact of the war in Ukraine

In February 2022, as a result because of the invasion of Ukraine by Russia, economic sanctions were imposed by the United States, the European Union, and certain other countries on Russian financial institutions and businesses. Due to the medical nature of our products, the current sanctions have not materially restricted the Company's our ability to continue selling many of our products to customers located in Russia. The Company also sources certain raw materials and components from Russia and Ukraine, and has taken actions to minimize the any adverse impacts from disrupted supply chains related to these items, the Company has purchased sufficient quantities for the near term, and is in the process of identifying alternative sources for the longer term. items. The Company's operations in Ukraine consist primarily of R&D activities, which continue uninterrupted from other locations in order to focus on the safety of employees. Overall, the Company's Company's operations in Russia and Ukraine have not been materially impacted by the conflict, and consequently, the Company has not recorded any allowance for doubtful accounts, inventory reserves, or asset impairments through the quarter three months ended September 30, 2023 March 31, 2024 as a result of these developments. the conflict.

For the quarter three months ended September 30, 2023 March 31, 2024, net sales in Russia and Ukraine were approximately 2% 1% of our consolidated net sales, and net assets in these countries were \$57 million \$70 million. These net assets include \$34 million \$44 million of cash and cash equivalents held within Russia as of September 30, 2023 March 31, 2024. Due to currency control measures imposed by the Russian government which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we may be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs, if at all.

While neither Russia nor Ukraine constitutes a material portion of our business, a significant escalation or expansion of economic disruption or the conflict's conflict's current scope could result in a loss of sales, disrupt our supply chain, broaden inflationary costs, and have a material adverse effect on our results of operations.

The impact of global economic conditions

Markets in several regions, particularly in Europe, have experienced continue to experience varying degrees of recessionary pressures and face continued concerns about the systemic impacts of adverse economic conditions and geopolitical issues. In addition, changes Changes in economic conditions, supply chain constraints, logistics challenges, higher energy costs, labor shortages, and the conflict in Ukraine, and geopolitical tensions in the Middle East, have all contributed to a period of higher inflation across the industry and the regions in which the Company operates.

As a result, the Company has experienced higher prices for certain raw materials, particularly for electronic components, which have in some cases required incremental procurement costs such as brokers' brokers' fees, during the year, and consequently a negative impact to on margins. The Company has also experienced delays in converting our backlog due to continued supply chain disruptions, which has negatively impacted both revenues and margins. Although the Company has experienced recent improvement in its supply chain, we We expect a continuation of these trends including disruptions and inflationary pressure on the cost of both raw material materials and wages in 2024, the effect of which will depend on the Company's our ability to successfully mitigate and offset the related impacts.

The deterioration in challenging macroeconomic conditions has also negatively affected impacted demand for the Company's Company's products and may continue to do so into in the future. Specifically, the increase in higher interest rates in the last twelve months has have put pressure on the ability and willingness of our customers to obtain financing for equipment purchases, which affects volumes for these products. Additionally, The Company has also faced additional competitive pressure for lower-priced options for investments in new equipment by dental practices, in particular for imaging products. While the recessionary environment in general particularly for certain regions Company has taken steps to address competitive pressures, such as southern Europe the reintroduction of its Orthophos SL 2D and 3D products, these trends may continue. While patient volumes have largely remained stable in the United States, the impact of macroeconomic declines and high interest rates has depressed demand been particularly apparent in Germany, which accounted for elective procedures including 10% of the Company's sales for the three months ended March 31, 2024. Germany was in a recession for most of implants 2023, largely due to persistent high inflation and aligner solutions. falling household spending, and near-term economic forecasts had not improved at the end of the first quarter of 2024. The Company believes the challenging macroeconomic and market conditions in Germany are likely to persist through at least the first half of 2024.

In anticipation of a continued inflationary trend and potentially deteriorating macroeconomic environment, the Company has we have attempted to mitigate these pressures through the following actions, among others:

- Driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation;
- Implementing cost-containment measures, as well as intensifying continuous improvement and restructuring programs in our manufacturing and distribution facilities and other areas of our business; and

- As explained further in the Results of Operations section below, the Company has partially offset these elevated costs in certain areas of the business with price increases during the year. increases. Should the higher inflationary environment continue, the Company we may be unable to raise the prices of our products and services sufficiently to keep up or engage in other cost cutting measures commensurate with the rate of inflation, which could have a material adverse effect on our results of operations and financial condition.

RESULTS OF OPERATIONS, OPERATIONS: THREE MONTHS ENDED SEPTEMBER 30, 2023 MARCH 31, 2024 COMPARED TO THREE MONTHS ENDED SEPTEMBER 30, 2022 MARCH 31, 2023

Net Sales

The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also presents the changes in net sales on an organic sales basis, which is a Non-GAAP measure. The Company defines "organic sales" "organic sales" as the reported net sales adjusted for: (1) net sales from acquired and divested businesses recorded prior to the first anniversary of the acquisition or divestiture; (2) net sales attributable to discontinued product lines in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's currency exchange rates.

Our measure of organic sales may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Organic sales is an important internal measure for the Company, and its senior management receives a monthly analysis of operating results that includes organic sales. The performance of the Company is measured on this metric along with other performance metrics.

The Company discloses changes in organic sales to allow investors to evaluate the performance of the Company's operations exclusive of the items listed above that may impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this supplemental information is helpful in understanding underlying net sales trends.

The Company's A reconciliation of net sales to organic sales for the three months ended September 30, 2023 and 2022, and a reconciliation to the percentage change in organic sales March 31, 2024 is as follows:

[illegible]

Percentages are based on actual values and may not reconcile due to rounding.

The slight decrease in organic sales was primarily due to weaker overall demand for Essential Dental Solutions and certain products in Connected Technology Solutions, particularly in Europe, and for our Connected Technology products as described below, mostly partially offset by price increases stronger demand for Orthodontic and strong demand in the Rest of World region. Implant Solutions products.

Net Sales by Segment

Connected Technology Solutions

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,	Three Months Ended March 31,	Three Months Ended March 31,
-------------------------------------	---------------------------------	------------------------------

(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$ Change	% Change	(in millions, except percentages)	2024	2023	\$ Change	% Change
Net sales										
Net sales										
Net sales	Net sales	\$276	\$286	\$ (10)	(3.8 %)		\$ 247	\$ 265	\$ (18)	(6.9 %)
Foreign exchange impact	Foreign exchange impact				0.8 %	Foreign exchange impact				(1.2 %)
Organic sales	Organic sales				(4.6 %)					
Organic sales										
Organic sales										

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to lower volumes of imaging equipment particularly and treatment centers, driven in Europe, part by competitive pricing pressures as well as unfavorable economic conditions in certain countries including Germany. These decreases were partially offset by increased higher volumes of CAD/CAM equipment in the United States and price increases, improved pricing as a result of lower targeted sales promotions in Europe.

Essential Dental Solutions

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,						Three Months Ended March 31,				
(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$ Change	% Change	(in millions, except percentages)	2024	2023	\$ Change	% Change
Net sales										
Net sales										
Net sales	Net sales	\$347	\$348	\$ (1)	(0.3 %)		\$ 364	\$ 386	\$ (22)	(5.9 %)
Foreign exchange impact	Foreign exchange impact				0.6 %	Foreign exchange impact				(0.4 %)
Organic sales	Organic sales				(0.9 %)					
Organic sales										
Organic sales										

Percentages are based on actual values and may not reconcile due to rounding.

The slight decrease in organic sales was primarily driven by weaker overall demand particularly in the United States and Europe, in part due to a benefit from satisfying backlog orders during the comparative quarter of 2023, partially offset by price increases and stronger demand in Rest of World, increases.

Orthodontic and Implant Solutions

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,						Three Months Ended March 31,				
(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$ Change	% Change	(in millions, except percentages)	2024	2023	\$ Change	% Change
Net sales										
Net sales										

Net sales	Net sales	\$252	\$247	\$	5	2.2 %		\$ 271	\$	\$ 259	\$	\$ 12		4.4	4.4 %
Foreign exchange impact	Foreign exchange impact					(1.5 %)	Foreign exchange impact								(1.2 %)
Organic sales	Organic sales					3.7 %									
Organic sales															
Organic sales															5.6 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by higher sales volumes of orthodontic aligners, for both our in-office and direct-to-consumer aligner solutions, particularly in the United States and Europe, and stronger demand for implants products in Rest of World. These increases were World, partially offset by lower volumes for implants and prosthetics products in the United States and Europe.

As a result of recent legislative changes in Nevada relating to teledentistry, we will discontinue new patient recruitment for our current direct-to-consumer aligner business model in the state, which we do not anticipate will have a material impact on our results. Currently in several other states, there are pending legislative or regulatory changes, or changes in the interpretation of existing legislation by regulators, that may impact the current business model and operations of our direct-to-consumer aligner business. As a result, we may need to evaluate new patient recruitment in certain states as we continue to assess these developments. We are developing new features and procedures for our direct-to-consumer aligner business models in response to existing and pending legislation. We continue to monitor these legal and regulatory developments to understand their potential impact on the operations of our direct-to-consumer aligner business. For additional information, see Part I, Item 1, "Business - Regulation" and Part 1, Item 1A, "Risk Factors" in our 2023 Form 10-K.

Wellspect Healthcare

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,							Three Months Ended March 31,						
Three Months Ended September 30,							Three Months Ended March 31,						
(in millions, except percentages)	(in millions, except percentages)	2023	2022	Change	% Change	(in millions, except percentages)	2024	2023	\$ Change	% Change			
Net sales	Net sales	\$72	\$66	\$	6	9.9 %	\$ 71	\$	\$ 68	\$	\$ 3	5.4	5.4 %
Foreign exchange impact	Foreign exchange impact				3.1 %	Foreign exchange impact							0.6 %
Organic sales	Organic sales				6.8 %								
Organic sales													
Organic sales													
Organic sales													

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was the result of a favorable mix of product sales across driven by higher volumes in all regions particularly in Europe, price increases, and favorable impact Rest of World, partly as a result of new product launches, partially offset by as well as a reduction in overall volumes, favorable impact from price increases.

Net Sales by Region

United States

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,							Three Months Ended March 31,						
Three Months Ended September 30,							Three Months Ended March 31,						

[illegible]

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily driven by higher volumes of orthodontic aligners within our direct-to-consumer aligner solutions and CAD/CAM products. These increases were partially offset by lower volumes of consumables products, imaging equipment, implants products, and implants Essential Dental Solutions products. Decreases in volumes for Essential Dental Solutions products were partially offset by price increases and higher volumes of orthodontic aligners. Sales for these products. Organic sales were also positively affected by higher wholesale volumes for of CAD/CAM products, but were not impacted by changes in dealer inventory levels during the quarter relative to the third quarter of the prior year due in part to timing of sales to distributors. 2023. Volumes for CAD/CAM products in both the third quarter of 2023 three months ended March 31, 2023 and 2024 included a seasonal build in distributor inventory of approximately \$20 million, compared to a smaller build in distributor inventory of approximately \$7 million during the same quarter of 2022. Despite this higher year over year seasonal build, distributor \$9 million. Distributor inventory levels for CAD/CAM products remained low as of the end of the third quarter 2023 relative to March 31, 2024 approximate historical averages.

Europe

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

		Three Months Ended September 30,											
		Three Months Ended March 31,				Three Months Ended March 31,							
(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$ Change	% Change	(in millions, except percentages)	2024		2023		\$ Change		% Change
Net sales													
Net sales													
Net sales	Net sales	\$354	\$358	\$ (4)	(1.1 %)		\$ 376	\$	\$ 396	\$	\$ (20)	(5.2	(5.2 %)
Foreign exchange impact	Foreign exchange impact												
Organic sales	Organic sales												
Organic sales													
Organic sales						(5.8 %)							

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to overall lower volumes for treatment centers and imaging Essential Dental Solutions products as well as endodontic and restorative consumables Connected Technology Solutions products as a result of less favorable market and macroeconomic trends, particularly in Germany. These decreases were partially offset by price increases as well as increased volumes for healthcare and orthodontic products. increases.

Rest of World

Net sales for the three months ended September 30, 2023 and 2022, and A reconciliation of net sales to organic sales for the three months ended March 31, 2024 is as follows:

Three Months Ended September 30,	Three Months Ended March 31,	Three Months Ended March 31,
-------------------------------------	---------------------------------	------------------------------

(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$	%	(in millions, except percentages)	2024		2023	\$ Change		% Change	
Net sales													
Net sales													
Net sales	Net sales	\$237	\$232	\$	5	2.0 %	\$ 221	\$	\$ 231	\$	(10)	(4.4)	(4.4 %)
Foreign exchange impact	Foreign exchange impact					(2.5 %)							(4.3 %)
Organic sales	Organic sales					4.5 %							
Organic sales													
Organic sales													(0.1 %)

Percentages are based on actual values and may not reconcile due to rounding.

The increase slight decrease in organic sales was primarily driven by improving declines in volumes for Connected Technology Solutions products, particularly CAD/CAM, price concessions, and lower demand in Japan. These decreases were mostly offset by increased volumes for both consumables products and implants products. In the third quarter of 2023, the The local volume-based procurement program in China continued to result in increased volumes for implants products, partially offset by price reductions, representing a marked improvement from the program's adverse impact earlier in 2023. These increases were partially offset by declines early 2023, however the growth rates in volumes China are expected to be more moderate for Connected Technology Solutions products. the remainder of 2024.

Gross Profit

Three Months Ended September 30,											
Three Months Ended March 31,											
Three Months Ended March 31,											
(in millions, except percentages)	(in millions, except percentages)					(in millions, except percentages)	2024	2023	\$ Change		% Change
		2023	2022	\$	%						
Gross profit	Gross profit	\$495	\$508	\$	(13)	(2.7 %)					
Gross profit											
Gross profit							\$ 506	\$ 519	\$	(13)	(2.5 %)
Gross profit as a percentage of net sales	Gross profit as a percentage of net sales	52.2 %	53.7 %		(150) bps						
Gross profit as a percentage of net sales											
Gross profit as a percentage of net sales											

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit for the quarter declined due to lower sales volumes described above, partially offset by the benefit of favorable product mix, price increases, lower distribution costs and favorable foreign currency translation. Gross profit as a percentage of net sales further declined due to inflation was flat for the quarter as higher manufacturing and input costs were offset by improved pricing as a result of material costs, higherlower targeted sales promotions, and a decrease in warranty costs and increased inventory obsolescence including product rationalization charges. compared to the three months ended March 31, 2023.

Operating Expenses

Three Months Ended September 30,											
Three Months Ended March 31,											
Three Months Ended March 31,											
(in millions, except percentages)	(in millions, except percentages)					(in millions, except percentages)	2024	2023	\$ Change		% Change
		2023	2022	\$	%						

During the three months ended September 30, 2023, the Company recorded net expense of \$6 million of restructuring and other costs, a decrease from the three months ended March 31, 2023, which consisted primarily of severance costs in conjunction with the restructuring plan announced in February 2023. For further details refer to Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

		Three Months Ended September 30,															
		Three Months Ended March 31,								Three Months Ended March 31,							
(in millions, except percentages)(a)	(in millions, except percentages)(a)	2023	2022	\$ Change	% Change	(in millions, except percentages)(a)	2024	2023	\$ Change	% Change	(in millions, except percentages)(a)	2024	2023	\$ Change	% Change		
Connected Technology Solutions	Connected Technology Solutions	\$ 22	\$ 25	\$ (3)	(12.0 %)	Connected Technology Solutions	\$ 22	\$ 25	\$ (3)	(12.0 %)	Connected Technology Solutions	\$ 22	\$ 25	\$ (3)	(12.0 %)		
Connected Technology Solutions						Connected Technology Solutions						Connected Technology Solutions					
Connected Technology Solutions						Connected Technology Solutions						Connected Technology Solutions					
Essential Dental Solutions						Essential Dental Solutions						Essential Dental Solutions					
Essential Dental Solutions						Essential Dental Solutions						Essential Dental Solutions					
Essential Dental Solutions	Essential Dental Solutions	115	110	5	4.5 %	Essential Dental Solutions	115	125	(10)	(7.5 %)	Essential Dental Solutions	115	125	(10)	(7.5 %)		
Orthodontic and Implant Solutions						Orthodontic and Implant Solutions						Orthodontic and Implant Solutions					
Orthodontic and Implant Solutions						Orthodontic and Implant Solutions						Orthodontic and Implant Solutions					
Wellspect Healthcare						Wellspect Healthcare						Wellspect Healthcare					
Wellspect Healthcare						Wellspect Healthcare						Wellspect Healthcare					
Wellspect Healthcare						Wellspect Healthcare						Wellspect Healthcare					

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

The decrease in segment adjusted operating income is due to lower organic sales noted above, increased warranty costs and an increase in SG&A headcount expenses due to reinvestment of some cost savings as well as unfavorable manufacturing leverage from reductions in headcount to fill key customer-facing roles, lower volumes. These decreases were partially offset by lower warranty costs, a reduction in professional services, advertising and selling related costs, and the favorable impact from foreign currency exchange translation.

The increase/decrease in segment adjusted operating income is due improved margins, favorable impact of product mix, reduction in professional services, and a favorable impact from foreign currency exchange. This was partially offset by/to the organic sales decrease noted above increased inventory obsolescence including product rationalization charges, and an increase in SG&A headcount expenses due to reinvestment/including an increase in selling related costs. These decreases were partially offset by the favorable impact of some cost savings from reductions in headcount to fill key customer-facing roles; foreign currency translation.

The decrease in segment adjusted operating income is due to inflation of material costs, an unfavorable impact from foreign currency exchange, higher inventory obsolescence expense during the period, and an increase in SG&A advertising and selling costs, and increased headcount expenses due to reinvestment of some cost savings from reductions in

headcount to primarily fill for key customer-facing roles. roles for direct-to-consumer aligner solutions. This was partially offset by the organic sales increase primarily for orthodontics products noted above.

Wellspect Healthcare

The increase in segment operating income results from the increase in sales noted above, as well as margin improvement due to the favorable manufacturing impact leverage of higher volumes. volumes, partially offset by unfavorable foreign currency translation.

Other Income and Expense

		Three Months Ended September 30,						Three Months Ended March 31,					
		Three Months Ended March 31,						Three Months Ended March 31,					
(in millions)	(in millions)	2023	2022	\$ Change	% Change	(in millions)		2024	2023	\$ Change		% Change	
Interest expense, net	Interest expense, net	\$ 18	\$ 14	\$ 4	24.5 %								
Interest expense, net	Interest expense, net												
Interest expense, net	Interest expense, net							\$ 18	\$ 20	\$ (2)		(11.7 %)	
Other (income) expense, net	Other (income) expense, net	(4)	9	(13)	NM	Other (income) expense, net		(7)	6	(13)	(13)	NM	NM
Net interest and other expense (income)	Net interest and other expense (income)	\$ 14	\$ 23	\$ (9)									

NM - Not meaningful

Interest expense, net

Interest expense, net for the three months ended September 30, 2023 increased March 31, 2024 decreased compared to the three months ended September 30, 2022 March 31, 2023, driven primarily by higher interest rates on lower short-term and other borrowings.

Other (income) expense, net

Other (income) expense, net for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023 is as follows:

		Three Months Ended September 30,		
(in millions)		2023	2022	\$ Change
Foreign exchange (gains) losses	\$	(5)	\$ 3	\$ (8)
Loss from equity method investments		1	4	(3)
Defined benefit pension plan expenses		1	2	(1)
Other non-operating income		(1)	—	(1)
Other (income) expense, net	\$	(4)	\$ 9	\$ (13)

Foreign exchange losses (gains) are primarily related to the revaluation of intercompany payables and loans, as well as a benefit in the three months ended September 30, 2023 from the Swiss franc foreign exchange forward contracts described in Note 9, Financial Instruments and Derivatives, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

		Three Months Ended March 31,		
(in millions)		2024	2023	\$ Change
Foreign exchange (gains) losses	\$	(9)	\$ 3	\$ (12)
Defined benefit pension plan expenses		2	2	—

Other non-operating income		—	1	(1)
Other (income) expense, net	\$	(7)	\$ 6	\$ (13)

Income Taxes and Net Income

Three Months Ended September 30,									
Three Months Ended March 31,					Three Months Ended March 31,				
(in millions, except percentages)	(in millions, except percentages)	2023	2022	\$	(in millions, except percentages)	2024	2023	\$ Change	
Provision (benefit) for income taxes	Provision (benefit) for income taxes	\$ 16	\$ (164)	\$ 180					
Provision (benefit) for income taxes									
Provision (benefit) for income taxes									
Effective income tax rate									
Effective income tax rate									
Effective income tax rate	Effective income tax rate	(6.3 %)	13.2 %						
Net loss attributable to Dentsply Sirona		\$ (266)	\$ (1,077)	\$ 811					
Net income (loss) attributable to Dentsply Sirona									
Net loss per common share - diluted									
		<u>\$ (1.25)</u>	<u>\$ (5.01)</u>						
Net income (loss) attributable to Dentsply Sirona									
Net income (loss) attributable to Dentsply Sirona									
Net income (loss) per common share - diluted									
Net income (loss) per common share - diluted									
Net income (loss) per common share - diluted									

Percentages are based on actual values and may not reconcile due to rounding.

Provision for income taxes

For The effective tax rate for the three months ended September 30, 2023 March 31, 2024 and 2023 was 44.9% and 18.4%, the income tax expense was \$16 million as compared respectively. The quarter to the income tax benefit of \$164 million during the three months ended September 30, 2022. The tax benefit in 2022 was driven by the tax-deductible goodwill and intangible impairment.

RESULTS OF OPERATIONS, NINE MONTHS ENDED SEPTEMBER 30, 2023 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2022

Net Sales

The Company's net sales for the nine months ended September 30, 2023 and 2022, and the reconciliation to organic sales are as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 2,953	\$ 2,939	\$ 14	0.5 %
Foreign exchange impact				(1.9 %)
Organic sales				2.4 %

Percentages are based on actual values and may not reconcile due to rounding.

The date increase in organic sales was led by performance in the Essential Dental Solutions and Orthodontic and Implant Solutions segments, primarily driven by price increases within both segments and higher volumes for orthodontic aligners. The increases were partially offset by lower volumes for implants and Connected Technology Solution products.

Net Sales by Segment

Connected Technology Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 850	\$ 875	\$ (25)	(2.9 %)
Foreign exchange impact				(2.3 %)
Organic sales				(0.6 %)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to lower volumes, particularly in Europe, partially offset by price increases and strengthening sales of new treatment centers and CAD/CAM products. Sales of CAD/CAM products in the United States were also positively impacted by the timing of sales to distributors relative to the first nine months of 2022 as explained below.

Essential Dental Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 1,110	\$ 1,084	\$ 26	2.3 %
Foreign exchange impact				(1.4 %)
Organic sales				3.7 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was due to price increases, as well as higher volumes of preventive and restorative products, particularly in the United States. These increases were partially offset by lower volumes of endodontic consumables.

Orthodontic and Implant Solutions

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 781	\$ 772	\$ 9	1.3 %
Foreign exchange impact				(2.1 %)
Organic sales				3.4 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by higher volumes of orthodontic aligners, particularly in the United States, coupled with an increase in volumes for implants and prosthetics products in Rest of World. This was partially offset by lower volumes of implants and prosthetics products in the other regions.

Wellspect Healthcare

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 212	\$ 208	\$ 4	2.3 %
Foreign exchange impact				(2.2 %)
Organic sales				4.5 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was the result of a favorable mix of product sales across all regions, particularly in Europe, and price increases.

Net Sales by Region

United States

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 1,069	\$ 1,023	\$ 46	4.5 %
Foreign exchange impact				— %
Organic sales				4.5 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was driven primarily by price increases and higher demand for consumables and orthodontics aligners. This was partially offset by lower volumes for imaging and implants products. Sales were also positively affected by wholesale volumes for CAD/CAM products relative to the first nine months of 2022 due in part to timing of sales to distributors. Volumes for CAD/CAM products in the first nine months of 2023 included a seasonal build in distributor inventory of approximately \$6 million compared to a reduction in distributor inventory of approximately \$32 million during the first nine months of 2022. Distributor inventory levels for CAD/CAM products remained low as of the end of the third quarter relative to historical averages.

Europe

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 1,153	\$ 1,183	\$ (30)	(2.5 %)
Foreign exchange impact				(1.3 %)
Organic sales				(1.2 %)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily driven by overall lower volumes for Connected Technology Solutions and Implants & Prosthetics Solutions products as a result of unfavorable market and macroeconomic trends, partially offset by price increases and higher volumes of orthodontic aligners.

Rest of World

Net sales for the nine months ended September 30, 2023 and 2022, and reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Net sales	\$ 731	\$ 733	\$ (2)	(0.3 %)
Foreign exchange impact				(5.5 %)
Organic sales				5.2 %

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by price increases and improved demand for Essential Dental Solutions products, as well as certain Connected Technology Solutions products, including treatment centers.

Gross Profit

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Gross profit	\$ 1,564	\$ 1,610	\$ (46)	(2.9 %)
Gross profit as a percentage of net sales	53.0 %	54.8 %	(180) bps	

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit declined due to foreign currency translation headwinds of \$26 million, higher warranty costs, increased inventory obsolescence including product rationalization charges, and higher material costs. These factors were partially offset by sales increases noted above, favorable sales mix driven by higher demand for higher margin consumables products, and improvements in the profitability of orthodontics products.

Operating Expenses

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Selling, general, and administrative expenses ("SG&A")	\$ 1,204	\$ 1,187	\$ 17	1.4 %
Research and development expenses	141	131	10	7.0 %
Goodwill and intangible asset impairments	307	1,281	(974)	NM
Restructuring and other costs	70	13	57	NM
SG&A as a percentage of net sales	40.8 %	40.4 %	40 bps	
R&D as a percentage of net sales	4.8 %	4.5 %	30 bps	

Percentages are based on actual values and may not reconcile due to rounding.

SG&A Expenses

SG&A expenses as a percentage of net sales increased in part due to professional service costs related to the restructuring and transformation initiatives, and an increase in travel as more customer-related interactions have returned to in-person format following the recovery from COVID-19. Headcount costs increased, primarily as a result of incremental investments in the Company's customer-facing roles, incentive compensation and merit increases. These increases were partially offset by a benefit from lower than expected severance costs due to a settlement, and lower advertising costs.

R&D Expenses

R&D expenses increased compared to the first nine months of 2022. The Company continues to prioritize ongoing investments in digital workflow solutions, product development initiatives, software development including clinical application suite and cloud deployment. The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

Goodwill and Intangible Asset Impairments

Goodwill and intangible asset impairments decreased compared to the nine months ended September 30, 2022, due to a lower level of impairment charges. For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Restructuring and Other Costs

During the nine months ended September 30, 2023, the Company recorded net expense of \$70 million of Restructuring and other costs which consist primarily of charges associated with the restructuring plan announced in February 2023. For further details, see Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Segment Adjusted Operating Income

(in millions, except percentages) ^(a)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Connected Technology Solutions	\$ 54	\$ 101	\$ (47)	(46.5 %)
Essential Dental Solutions	365	361	4	1.1 %
Orthodontic and Implant Solutions	129	157	(28)	(17.8 %)
Wellspect Healthcare	65	57	8	14.0 %

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

Connected Technology Solutions

The decrease in segment adjusted operating income effective tax rate is due to an increase in SG&A costs including increased headcount primarily for key customer-facing roles, unfavorable impact from product a valuation allowance and a shift in geographical mix inflation of material costs, increased warranty costs, and an increase in inventory obsolescence expense, partially offset by the organic sales increase noted above.

Essential Dental Solutions earnings towards jurisdictions with higher statutory tax rates.

The increase Company performed an assessment to evaluate the new global minimum tax developed by the Organisation for Economic Co-operation and Development ("Pillar Two"), which involved analyzing the tax laws in segment adjusted operating income is due to each jurisdiction in which the organic sales increase noted above partially offset by an increase in SG&A costs including headcount increase for customer-facing roles Company operates and trade event related expenses, inflation of material costs, and an unfavorable impact from product mix.

Orthodontic and Implant Solutions

The decrease in segment adjusted operating income is due to modeling the unfavorable implications with the Pillar Two framework. The impact of foreign currency exchange, inflation of material costs, and an increase in SG&A costs including increased headcount primarily for key customer-facing roles, and sales event related expenses partially offset by Pillar Two on the organic sales increase and improved profitability for orthodontics products noted above.

Wellspect Healthcare

Company was not significant. The increase in segment adjusted operating income resulted from Company included the increase in organic sales noted above, as well as margin improvement due to the favorable manufacturing impact of higher volumes.

Other the top-up tax under the Income and Expense

(in millions, except percentages)	Nine Months Ended September 30,			
	2023	2022	\$ Change	% Change
Interest expense, net	\$ 58	\$ 41	\$ 17	40.3 %
Other (income) expense, net	16	20	(4)	NM
Net interest and other expense	\$ 74	\$ 61	\$ 13	

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

Interest expense, net

Interest expense, net Inclusion Rule for those jurisdictions in which the nine months ended September 30, 2023 increased by \$17 million compared to Company failed the nine months ended September 30, 2022, driven primarily by higher interest rates on short-term and other borrowings.

Other (income) expense, net

Other (income) expense, net for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 was as follows:

(in millions)	Nine Months Ended September 30,		
	2023	2022	\$ Change
Foreign exchange losses (gains)	\$ 7	\$ (1)	\$ 8
Loss from equity method investments	4	14	(10)
Defined benefit pension plan expenses	5	6	(1)
Other non-operating loss	—	1	(1)
Other (income) expense, net	\$ 16	\$ 20	\$ (4)

Foreign exchange losses (gains) are primarily related to the revaluation of intercompany payables and loans, as well as a benefit transitional safe harbor requirement in the first nine months of 2023 from the Swiss franc foreign exchange forward contracts described in Note 9, Financial Instruments and Derivatives, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.

Income Taxes and Net Income

(in millions, except per share amounts and percentages)	Nine Months Ended September 30,		
	2023	2022	\$ Change

Benefit for income taxes	\$ (28)	\$ (128)	\$ 100
Effective income tax rate	12.1 %	12.1 %	
Net loss attributable to Dentsply Sirona	\$ (199)	\$ (935)	\$ 736
Net loss per common share - diluted	\$ (0.94)	\$ (4.34)	

Percentages are based on actual values and may not reconcile due to rounding.

Provision for income taxes

For the nine months ended September 30, 2023, the income tax benefit was \$28 million as compared to the tax benefit of \$128 million during the nine months ended September 30, 2022. The tax benefit in the current period was driven by the partial valuation allowance release of net operating loss carryforwards due to the Company's ability to project future taxable income as a result of internal debt restructurings. The tax benefit in 2022 was driven by the tax-deductible goodwill and intangible impairment rate.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the critical accounting policies as disclosed in the 2023 Form 10-K.

Goodwill Impairment and Indefinite-Lived Intangible Assets

Goodwill

Goodwill represents the excess cost over the fair value of the identifiable net assets of businesses acquired. Goodwill is not amortized; instead, it is tested for impairment at the reporting unit level annually at April 1 or more frequently if events or circumstances indicate that the carrying value of goodwill may be impaired, or if a decision is made to sell a business. Judgment is involved in determining if an indicator of impairment has occurred during the course of the year. Such indicators may include a decline in expected cash flows, unanticipated competition, increased interest rates, or slower growth rates, among others. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. It is important to note that fair values which could be realized in an actual transaction may differ from those used to evaluate the impairment of goodwill.

For the three months ended March 31, 2024, the Company did not identify any indicators of a more likely than not impairment related to its goodwill balances which would require an interim quantitative assessment. Refer to Part I, Item 1, Note 13, Goodwill is allocated among reporting units and evaluated Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q for further discussion of the Company's annual and interim goodwill impairment at that level. The Company's reporting units are either an operating segment or one level below its operating segments, as determined in accordance with ASC 350. testing.

Indefinite-Lived Intangible Asset Impairment Assets

Indefinite-lived intangible assets consist of tradenames, trade names, trademarks and in process in-process R&D and are not subject to amortization; instead, they are tested for impairment annually or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired or if a decision is made to sell a business. A significant amount of judgment is involved in determining if an indicator of impairment has occurred during the year. Such indicators may include a decline in expected cash flow, unanticipated competition, increased interest rates, or slower growth rates, among others. It is important to note that fair values that could be realized in an actual transaction may differ from those used to evaluate the impairment of indefinite-lived assets.

The fair value of acquired tradenames, trade names and trademarks is estimated by the use of using a relief from royalty method, which values an indefinite-lived intangible asset by estimating the royalties saved through the ownership of an asset. Under this method, an owner of an indefinite-lived intangible asset determines the arm's length royalty that likely would have been charged if the owner had to license the asset from a third party. The royalty rate, which is based on the estimated rate applied against forecasted sales, is tax-effected and discounted at present value using a discount rate commensurate with the relative risk of achieving the cash flow attributable to the asset. Management judgment is necessary to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. Other assumptions are consistent with those applied to goodwill impairment testing. Alternatively, the Company may assess indefinite-lived intangible assets qualitatively.

The determination of fair value involves uncertainties around the forecasted cash flows as it requires management to make assumptions and apply judgment to estimate future business expectations. Those future expectations include, but are not limited to, macroeconomic factors such as higher cost of capital, cost inflation, unfavorable foreign currency impacts, and increased supply chain costs and new product development changes for these reporting units.

Any deviation in actual financial results compared to the forecasted financial results or valuation assumptions used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company's future asset impairment testing will not result in a material charge to earnings.

Goodwill and Indefinite-Lived Intangible Asset Impairment Results

The Company previously assessed the goodwill of its reporting units and its indefinite-lived intangible assets for impairment as of April 1, 2023. Based on that annual impairment test, which computed fair values of reporting units using a discounted cash flow model with inputs developed using both internal and market-based data, it was determined that the fair values of its reporting units and indefinite-lived intangible assets more likely than not exceeded their carrying values, resulting in no impairment.

In the quarter three months ended September 30, 2023 March 31, 2024, the Company identified indicators of a "more more likely than not" not impairment related to its Connected Technology Solutions reporting unit, which comprises all of certain indefinite-lived imaging product trade names within the Connected Technology Solutions segment. The decline in fair value for this reporting unit of these indefinite-lived trade names was driven by adverse macroeconomic factors declines in volumes during the first quarter of 2024, which was due in part to a loss in market share from competitive pricing pressures, as a result of weakened demand particularly well as unfavorable economic conditions in European markets and increased discount rates. Since the second quarter, core underlying market interest rates, which serve as the basis for the discount rate assumptions in our impairment models, rose by approximately 110 basis points, certain markets. These factors are contributing contributed to reduced forecasted revenues lower operating margins, and reduced expectations for future cash flows in the near term, particularly term. The trade names were evaluated for demand for products which are commonly financed by end customers which are adversely impacted by impairment using an environment income approach, specifically a relief from royalty method. Significant assumptions used in the relief from royalty method included, but were not limited to, a discount rate of higher interest 11%, revenue growth rates (including perpetual growth rates), and royalty rates. As a result, the Company recorded a pre-tax goodwill impairment charge as of September 30, 2023 related to the Connected Technology Solutions reporting unit of \$291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment.

Additionally, in conjunction with the goodwill impairment test in the quarter ended September 30, 2023, the Company tested the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment for impairment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment, and determined certain tradenames and trademarks were impaired. As a result, the Company recorded indefinite-lived intangible asset impairment charges charge of \$14 million and \$2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, \$6 million for the three months ended September 30, 2023 March 31, 2024. The impairment charge remaining carrying value of this intangible asset group was primarily driven by macroeconomic factors such \$22 million as weakened demand, higher cost of capital, and cost inflation, which are contributing to reduced forecasted revenues, March 31, 2024. As the fair value of these indefinite-lived intangible assets approximate approximates carrying value, as of September 30, 2023, any further decline in key assumptions could result in additional impairment in future periods.

the future. Refer to Part I, Item 1, Note 13, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q for further discussion of the Company's annual and interim goodwill and indefinite-lived intangible asset impairment testing.

Based on the interim quantitative and qualitative assessments performed for the Company's other indefinite-lived intangible assets and reporting units, the Company believes there is no indication that the carrying value more likely than not exceeds the fair value in each case as of March 31, 2024; therefore, the Company did not identify any indicators of a more likely than not impairment related to its goodwill or intangible assets, other than as noted above. However, any further deterioration in key assumptions could result in impairment charges in the future. The Company applied a hypothetical sensitivity analysis by increasing the discount rate of these indefinite-lived intangible assets and reporting units by 100 basis points. As of March 31, 2024, the estimated fair value of the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment exceeded carrying value by less than 15%. If discount rates were hypothetically increased by 100 basis points, this reporting unit would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was \$1,148 million at March 31, 2024.

LIQUIDITY AND CAPITAL RESOURCES

Nine Months Ended September 30,		Three Months Ended March 31,			Three Months Ended March 31,		
		\$					
(in millions)	(in millions)	2023	2022	Change	(in millions)	2024	2023
Cash (used in) provided by:					\$ Change		
Cash (used in) provided by:							
Cash (used in) provided by:							
Cash (used in) provided by:							
Operating activities							
Operating activities							
Operating activities	Operating activities	\$217	\$375	\$ (158)			
Investing activities	Investing activities	(69)	(109)	40			
Financing activities	Financing activities	(179)	(168)	(11)			

Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(25)	(19)	(6)
Net (decrease) increase in cash and cash equivalents	Net (decrease) increase in cash and cash equivalents	\$ (56)	\$ 79	\$ (135)

Cash provided by operating activities decreased increased compared to the nine three months ended September 30, 2022 March 31, 2023, primarily as a result of changes in working capital including higher collections on accounts receivable which were outstanding at the beginning of the period, and a lower collections from sales build of inventory during the current period, higher operating expenses, and timing of payments to vendors. period. These decreases increases in operating cash were offset by other changes in working capital including a lower build of inventory higher payments to vendors during the current period. period due to timing. At September 30, 2023 March 31, 2024, the number of days for sales outstanding in accounts receivable increased by 6 days 1 day to 61 60 days as compared to 55 59 days at December 31, 2022 December 31, 2023, and the number of days of sales in inventory increased by 12 days to 138 128 days at September 30, 2023 March 31, 2024 as compared to 137 126 days at December 31, 2022 December 31, 2023.

The decrease in cash used in investing activities was increased compared to the three months ended March 31, 2023, primarily due to higher net cash received paid on settlement of derivatives of \$29 million and \$11 million, offset by lower capital expenditures of \$8 million \$5 million. The Company estimates capital expenditures to be in the range of approximately \$140 million \$170 million to \$160 million \$200 million for the full year 2023 2024 and expects these investments to include implementation expenses for a new global Enterprise Resource Planning ("ERP") system, equipment upgrades, and capacity expansion of facilities to provide incremental space for growth support product innovation and the consolidation of operations consolidate operations for enhanced efficiencies, as well as capital investment related to modernizing our integrated financial systems and enterprise resource planning across the business. efficiencies.

The increase of cash used in financing activities compared to the nine three months ended September 30, 2022 March 31, 2023 was primarily driven by higher dividends paid a reduction in short-term borrowing of \$8 million \$175 million partially offset by the reduction in share repurchases of \$150 million. During the three months ended March 31, 2024, lower proceeds from the exercise of stock options of \$6 million and higher short-term borrowings of \$4 million. The Company's total borrowings increased by a net \$46 million during the nine months ended September 30, 2023 \$28 million, mainly due to the use of the Company's commercial paper program, partially offset by a decrease of \$17 million \$45 million due to exchange rate fluctuations on debt denominated in foreign currencies.

During On November 7, 2023, the nine months ended September 30, 2023 Board of Directors approved an increase to the authorized share repurchase program of \$1.0 billion. At March 31, 2024, the Company entered into an accelerated share repurchase agreement ("ASR Agreement") of \$150 million with approximately 3.1 million shares delivered during March 2023 at a volume-weighted average price of \$38.74 representing \$120 million of the total anticipated repurchase. In April 2023, an additional 0.8 million shares were delivered upon the final settlement of the ASR Agreement resulting in a total 3.9 million shares repurchased under the agreement. At September 30, 2023, \$590 million had \$1.44 billion of authorization remained remaining available for future share repurchases. Additional share repurchases, if any, may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company deems considers appropriate based upon prevailing market and business conditions and other factors. The Company intends to repurchase up to \$150 million of shares in the second quarter of 2024. At September 30, 2023 March 31, 2024, the Company held 52.7 million 56.9 million shares of treasury stock.

The Company's ratio of total net debt to total capitalization was as follows:

(in millions, except percentages)	(in millions, except percentages)	September 30, 2023	December 31, 2022	(in millions, except percentages)	March 31, 2024	December 31, 2023
Current portion of debt		\$ 187	\$ 118			
Notes payable and current portion of debt						
Notes payable and current portion of debt						
Notes payable and current portion of debt						
Long-term debt	Long-term debt	1,803	1,826			
Less: Cash and cash equivalents	Less: Cash and cash equivalents	309	365			
Net debt	Net debt	\$ 1,681	\$ 1,579			
Total equity	Total equity	3,371	3,812			

Total equity			
Total equity			
Total capitalization	Total capitalization	\$ 5,052	\$ 5,391
Total net debt to total capitalization ratio	Total net debt to total capitalization ratio	33.3 %	29.3 %
Total net debt to total capitalization ratio			
Total net debt to total capitalization ratio		35.6 %	35.1 %

At September 30, 2023 March 31, 2024, the Company had a total remaining borrowing capacity \$475 million of \$562 million borrowings available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company's Company's borrowing capacity includes a \$700 million multi-currency credit facility available through which expires in May 2028. The Company also has available access to an aggregate \$500 million under a U.S. dollar commercial paper facility. The \$700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is \$700 million. The Company had \$165 million \$249 million outstanding borrowings under the commercial paper facility at September 30, 2023 March 31, 2024 resulting in \$535 \$451 million remaining available under the revolving credit and commercial paper facilities. The Company also has access to \$48 million \$43 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At September 30, 2023 March 31, 2024, the Company had \$21 million \$19 million outstanding under short-term borrowing arrangements.

The Company's revolving credit facility, term loans and senior notes contain certain covenants relating to the Company's Company's operations and financial condition. The most restrictive of these covenants are: (1) a ratio of total debt outstanding to total capital not to exceed 0.6, and (2) a ratio of operating income excluding depreciation and amortization to interest expense of not less than 3.0 times, in each case, as such terms are defined in the relevant agreement. Any breach of any such covenants would result in a default under the existing debt agreements that would permit the lenders to declare all borrowings under such debt agreements to be immediately due and payable and, through cross default provisions, would entitle the Company's Company's other lenders to accelerate their loans. At September 30, 2023 March 31, 2024, the Company was in compliance with these covenants.

The Company expects on an ongoing basis to be able to finance operating cash requirements, capital expenditures, and debt service from the current cash, cash equivalents, cash flows from operations and amounts available under its existing borrowing facilities. The Company's Company's credit facilities are further discussed in Note 12, Financing Arrangements, to the Unaudited Consolidated Financial Statements of this Form 10-Q.

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' subsidiaries' operating activities and future foreign investments. The Company has the ability to repatriate cash to the United States, which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At September 30, 2023 March 31, 2024, management believed that sufficient liquidity was available in the United States and expects this to remain continue for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations, however, these particular repatriation operations. Repatriation activities both performed and contemplated to date have not resulted in, and are not expected to result in, a any significant incremental tax liability to the Company.

The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near-term based on strategic capital management. The Company believes there is sufficient liquidity available for the next twelve months.

Material Trends in Capital Resources

On February 14, 2023, the Board of Directors of the Company approved a plan to restructure the Company's business to improve operational performance and drive shareholder value creation. The plan includes a restructuring of the business through a new operating operating model with five global business units, optimization of central functions and overall management infrastructure, and other efforts aimed at cost savings. The restructuring plan anticipates a reduction in the Company's global workforce of approximately 8% to 10%, subject to co-determination processes with employee representative groups in countries where required. required. The plan is expected to be substantially completed by mid-2024 in 2024 and result in \$200 to \$225 million approximately \$200 million in annual cost savings. Some of the The reduction in headcount and cost savings related to this plan is expected to be offset as the Company makes additional investments including in sales personnel, our new global ERP system, and other customer-facing roles. transformation initiatives.

As of September 30, 2023 March 31, 2024, in conjunction with this plan, the Company has incurred \$65 million incurred \$67 million in restructuring charges, from inception, primarily related to employee transition, severance payments, employee benefits, and facility closure costs and \$14 million \$20 million in other non-recurring costs related to the restructuring activity activities which mostly consist of consulting, legal and other professional service fees. The Company expects to incur between \$115 \$115 million to \$135 million in one-time charges, comprising of \$80 \$80 million to \$100 million in restructuring expenditures and charges and \$35 million in other non-recurring charges, the majority of which are expected to be incurred as cash expenditures in 2023. charges. The estimates of these charges and their timing are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur other charges or cash expenditures in connection with this plan which are not currently contemplated. For further details refer to Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Beginning in the second quarter of 2022, the Company's financial results have also been impacted by the costs associated with the internal investigation conducted and completed by the Audit and Finance Committee and subsequently, associated litigation and the external investigation by the SEC which is currently in progress, are ongoing. These costs have included legal expenses as well as third party accounting and other professional service fees in conjunction with the investigations and subsequent remediation activities still underway. Additionally, the Company has incurred severance costs associated with its remedial personnel actions, as well as special one-time costs in connection with retention of key personnel. These costs totaled approximately \$61 million for the year ended December 31, 2022, with additional costs of \$14 million \$19 million incurred in for the nine months year ended September 30, 2023 December 31, 2023. The costs in 2023 were offset by a \$17 million gain from release of employee compensation accruals resulting from a settlement in in the three months ended September 30, 2023. Costs related to remediation activities described in Part I, Item 4 Controls and Procedures of this Form 10-Q are expected to continue further into 2023, and March 31, 2024, the Company will continue to incur recorded \$2 million of similar costs, including legal defense costs into 2024 expenses pertaining to the matters described in Note 14, Commitments and Contingencies in the Notes to the Unaudited Consolidated Financial Statements. Statements, and expects that it will continue to incur such costs for the remainder of 2024.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Part I, Item 1, Note 1, Business and Basis of Presentation, to the Unaudited Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

As described in Part I, Item 1, Note 9, Financial Instruments and Derivatives to the Unaudited Consolidated Financial Statements, the Company entered into Swiss franc foreign exchange contracts designated as a net investment hedge. Partly as a result of this activity, at September 30, 2023 a 10% weakening of the U.S. dollar against all other currencies would decrease the net fair value associated with the Company's forward foreign exchange contracts by approximately \$99 million. There have been no other material changes from the information provided in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in our Annual Report on 2023 Form 10-K filed on March 1, 2023 (the "2022 Form 10-K").10-K.

Item 4 – Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company has established Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures designed to provide reasonable assurance as of the end of the period covered by this report. Based on that information required to be disclosed evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in the reports we file or submit Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934, as amended, (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

The Company's management, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of September 30, 2023, the end of the period covered by this report, and concluded the Company's disclosure controls and procedures are not effective due to the material weaknesses in internal control over financial reporting as described below under "Material Weaknesses in Internal Control over Financial Reporting."

Material Weaknesses in Internal Control over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

As described in the Explanatory Note to the Form 10-K for the year ended December 31, 2021, as amended and filed on November 7, 2022, management identified the following material weaknesses in the Company's internal control over financial reporting, which continue to exist as of September 30, 2023:

- a. The Company did not design and maintain an effective internal control environment, as former management failed to set an appropriate tone at the top. Specifically, certain members of senior management, including the Company's former Chief Executive Officer and former Chief Financial Officer, engaged in conduct that was inconsistent with the Company's culture of compliance and Code of Ethics and Business Conduct.
- b. The Company did not maintain a sufficient complement of personnel with an appropriate level of knowledge about accounting for variable consideration related to customer incentive arrangements in a manner commensurate with our financial reporting requirements.

These material weaknesses contributed to the following additional material weakness:

- c. The Company did not design and maintain effective controls associated with approving, communicating, and accounting for incentive arrangements with customers, impacting the completeness and accuracy of revenues, including variable consideration.

As previously disclosed in the Company's Current Report on Form 8-K filed August 2, 2023, subsequent to the filing of the Company's Quarterly Report on Form 10-Q filed May 3, 2023, management identified the following additional material weakness in the Company's internal control over financial reporting, which continues to exist as of September 30, 2023:

- d. The Company did not design and maintain effective controls relating to the segregation of duties specific to the creation of manual journal entries.

Each of these material weaknesses could result in a misstatement of substantially all of our account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

As of the filing of this Form 10-Q, the material weaknesses described above have not been remediated. The material weaknesses described above cannot be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. Based on the implementation of these remedial actions, we will continue to monitor and test controls for effectiveness through the end of the observation period. Accordingly, management will continue to monitor and evaluate the effectiveness of our internal control over financial reporting in the activities affected by the material weaknesses described above.

Remediation Plan and Status

While the material weaknesses previously disclosed have not yet been remediated as of September 30, 2023, management has devoted substantial resources to the implementation of remediation efforts to address the material weaknesses described herein, as well as other identified areas of risk. These efforts, summarized below, which have been implemented and are currently being tested for their effectiveness in remediating the identified material weaknesses, are also intended to enhance the Company's overall internal control over financial reporting and disclosure controls and procedures.

With oversight from the Audit and Finance Committee and input from the Board of Directors, management has enhanced and implemented changes in processes, systems, and controls intended to remediate the material weaknesses described in the Material Weaknesses in Internal Control over Financial Reporting section above and to improve our internal control over financial reporting as noted below. Management and the Board of Directors, including the Audit and Finance Committee, are working to remediate the material weaknesses identified herein. Actions taken to date include:

- a. Appointment of a new Chief Executive Officer, a new Chief Financial Officer and a new Chief Accounting Officer;
- b. Termination of certain members of senior management as well as non-executive employees for violations of the Code of Ethics and Business Conduct;
- c. Reviewed and enhanced the Company's Code of Ethics and Business Conduct including to clarify responsibilities related to the Company's financial reporting and disclosures;
- d. Implemented general training programs on revenue recognition for commercial and finance personnel;
- e. Established requirements and provided trainings for employees who have a role in negotiating, assessing, agreeing, and accounting for customer incentive arrangements with distributors;
- f. Implemented commercial contracting policies and provided training on new processes to individuals responsible for execution, oversight and review of customer incentive arrangements with customers;
- g. Implemented written policies and procedures to provide governance and establish responsibility for oversight of incentive arrangements provided to customers in North America, including the appropriate delegation of authority for such approvals;
- h. Provided incremental training to Company personnel on the updated Code of Ethics and Business Conduct;
- i. Implemented written policies and procedures to require review and approval of and establish oversight responsibility over incentive arrangements provided to customers in China, including the appropriate delegation of authority for such approvals;
- j. Formalized written policies and procedures to provide governance and establish responsibility for guidelines, documentation and oversight of product returns from customers when a contractual right to return exists in a customer agreement;
- k. Enhanced processes to ensure all applicable terms and conditions for incentive-based programs and customer agreements are timely communicated to individuals responsible for accounting and financial reporting;
- l. Strengthened internal controls over the accounting for customer incentive arrangements, including implementing: (i) formal controls to continuously review and document the methodology and assumptions used in estimating variable based incentives and (ii) formal controls to ensure the accuracy of the estimated accrued liability analysis;
- m. Evaluated finance and commercial operations talent and address identified gaps; and
- n. Established a recurring cadence for future training programs on revenue recognition for commercial and finance personnel.

In addition, the Company took the following remedial actions to improve disclosure controls and procedures:

- a. Enhanced existing Disclosure Committee responsibilities through adoption of a formal charter, which identifies members and sets forth the roles and responsibilities of the Disclosure Committee, among other requirements; and
- b. Implemented additional and enhanced existing sub-certifications and internal management representation letters, including providing training on the purpose of the sub-certification and the process for evaluating the representations.

In connection with the material weakness relating to segregation of duties specific to the creation of manual journal entries, the Company took the following remedial actions:

- a. Implemented further segregation of duties in the performance of controls around manual journal entries, including implementing restrictions to user access rights in our general ledger systems to post manual journal entries, to ensure that reviewers of manual journal entries do not also have the ability to create and post such entries;
- b. Modified existing processes to enhance use of approval workflows in our process to document, support and review manual journal entries; and
- c. Enhanced the global policy on manual journal entries, including appropriate entry approval authorization and training of requisite personnel.

Under the direction of the Audit and Finance Committee, Management has overseen the planning and effective execution of the remediation efforts described above. Management believes the foregoing efforts have effectively addressed the material weaknesses described above; however, more time is needed for the improved controls to operate and undergo testing of effectiveness before they can be deemed remediated. As the Company continues to evaluate and improve its internal control over financial reporting and disclosure controls and procedures, management may determine to take additional measures to improve controls or determine to modify the remediation plan described above. Procedures to implement and evaluate this remediation plan have to date required significant amounts of time, allocation of internal resources and external costs, and remaining remediation activities of testing and demonstrating operating effectiveness of these controls will continue to place significant demands on financial and operational resources until these remaining efforts are completed.

Changes in Internal Control Over Financial Reporting

Except for progress made on the remediation activities described in the Remediation Plan and Status section above, there have been no changes in the Company's internal control over financial reporting that occurred during the three months ended September 30, 2023 March 31, 2024 that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings

Refer to Part I, Item 1, Note 14 Commitments and Contingencies, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Item 1A – Risk Factors

We have updated two risk factors as disclosed in Part I, Item 1A, "Risk Factors" in the 2022 Form 10-K, as amended, as follows:

We have recognized substantial goodwill and indefinite-lived intangible asset impairment charges, most recently in the September 2023 quarter, and may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future.

We review amortizable intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. We test goodwill and indefinite-lived intangibles for impairment at least annually. The valuation models used to determine the fair value of goodwill or indefinite-lived intangible assets are dependent upon various assumptions and reflect management's best estimates. We have acquired other companies and intangible assets and may not realize all the economic benefit from those acquisitions, which could cause an impairment of goodwill or intangibles.

The goodwill and indefinite-lived intangible asset impairment analyses are sensitive to changes in key assumptions used, such as discount rates, revenue growth rates, perpetual revenue growth rates, operating margin percentages, and net working capital assumptions of the business as well as current market conditions affecting the dental and medical device industries in both the U.S. and globally. Given the uncertainty in the marketplace and other factors affecting management's assumptions underlying our discounted cash flow model, the assumptions and projections used in the analyses may not be realized and our current estimates could vary significantly in the future, which may result in an additional goodwill or indefinite-lived intangible asset impairment charge at that time.

In the quarter ended September 30, 2023, the Company identified indicators of a "more likely than not" impairment related to its Connected Technology Solutions reporting unit, which comprises all of the Connected Technology Solutions segment. As a result, the Company recorded a pre-tax goodwill impairment charge as of September 30, 2023 related to the Connected Technology Solutions reporting unit of \$291 million, resulting in a full write-off of the remaining goodwill balance for the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment.

Additionally, in conjunction with the goodwill impairment test in the quarter ended September 30, 2023, the Company tested the long-lived intangible assets related to the businesses within the Connected Technology Solutions reporting unit within the Connected Technology Solutions segment for impairment. The Company also identified an indicator of impairment for the indefinite-lived intangible assets within the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment, and determined certain tradenames and trademarks were impaired. As a result, the Company recorded indefinite-lived intangible asset impairment charges of \$14 million and \$2 million for the Connected Technology Solutions and Orthodontic and Implant Solutions segments, respectively, for the three months ended September 30, 2023. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2023, any further decline in key assumptions could result in additional impairment in future periods. At September 30, 2023, the Company has \$431 million of indefinite-lived intangible assets and \$2.4 billion of goodwill recorded on its balance sheet.

For the three months ended September 30, 2023, the Company considered qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in the likelihood that the goodwill or indefinite-lived intangible assets may have become more likely than not impaired during the course of the quarter. For the reporting units and indefinite-lived intangible assets for which no triggering event was identified, the Company performed a hypothetical sensitivity analysis by increasing the discount rate by 100 basis points. If discount rates were hypothetically increased by 100 basis points at September 30, 2023, the Implants & Prosthetics reporting unit within the Orthodontic and Implant Solutions segment would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was \$1,133 million at September 30, 2023. Additionally under this sensitivity, certain indefinite-lived intangibles within the Connected Technology Solutions and Essential Dental Solutions segments would have a fair value less than 10% in excess of carrying value. The carrying value of these indefinite-lived intangible assets within the aforementioned segments was \$27 million and \$7 million, respectively, at September 30, 2023. Refer to Part I, Item 1, Note 13, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements for further discussion of the Company's goodwill and indefinite-lived intangible asset impairment testing.

Due to the international nature of our business, including increasing exposure to markets outside of the U.S., political or economic changes or other factors could harm our business and financial performance.

Approximately two-thirds of our sales are located in regions outside the U.S. In addition, we anticipate that sales outside of the U.S. will continue to expand and account for a significant portion of our revenue. Operating internationally is subject to a number of uncertainties, including, but not limited to, the following:

- economic and political instability;
- import or export licensing requirements;
- additional compliance-related risks;
- trade restrictions and tariffs;
- product registration requirements;
- longer payment cycles;
- changes in regulatory requirements and tariffs, including recent restrictions in China on the proportion of certain medical equipment which can be imported;
- potentially adverse tax consequences; and
- trade policy changes

Changes in or the imposition of tariffs could make it more difficult or costly for us to export our products to other countries. These measures could also result in increased costs for goods imported into the U.S. This in turn could require us to increase prices to our customers which may reduce demand, or, if we are unable to increase prices, result in lowering our margin on products sold. We cannot predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business. The adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies has the potential to adversely impact demand for our products, our costs, our customers and our suppliers, which in turn could adversely impact our business, financial condition and results of operations.

Certain of these risks may be heightened as a result of changing political climates which may lead to changes in areas such as trade restrictions and tariffs, regulatory requirements and exchange rate fluctuations, which may adversely affect our business and financial performance. For example, as a result of escalating tensions and the subsequent invasion of Ukraine by Russia, the U.S., other North Atlantic Treaty Organization member states, the EU and other countries have imposed sanctions on Russia, including its major financial institutions and certain other businesses and individuals, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People's Republic and the so-called Luhansk People's Republic. Russia also imposed significant currency control measures aimed at restricting the outflow of foreign currency and capital from Russia, imposed various restrictions on transacting with non-Russian parties, banned exports of various products, and imposed other economic and financial restrictions. These include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia. Russia may further respond in kind, and the continuation of the conflict may result in additional sanctions being enacted by the U.S., other North Atlantic Treaty Organization member states, the EU or other countries. The length, impact, and outcome of this ongoing military conflict is highly unpredictable and could lead to significant market and other disruptions, which, along with the spillover effect of ongoing civil, political and economic disturbances on surrounding areas, may significantly devalue currencies utilized by us or have other adverse impacts including increased costs of raw materials and inputs, manufacturing or shipping delays or increases in inflation rate, cyber attacks and supply chain challenges. Export controls implemented as part of sanctions could also restrict the sale of equipment or products containing U.S. developed software and technology into Russia.

For the quarter ended September 30, 2023, net sales in Russia and Ukraine were approximately 2% of our consolidated net sales, and net assets in these countries were \$57 million. These net assets include \$34 million of cash and cash equivalents held within Russia as of September 30, 2023. Due to currency control measures imposed by the Russian government which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we may be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs, if at all.

The recent terrorist attacks by Hamas militants crossing the border from Gaza to Israel in October 2023 and the subsequent military response by the Israeli government has resulted in significant unrest and uncertainty within that region, including the possibility that escalating violence and involvement of other terrorist groups from neighboring countries may further impact our employees and operations. The Company's operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one in southern Israel, and employs approximately 315 associates. These facilities remain open and continue to operate. We may, however, determine to discontinue production for the safety of our employees, or we could face future production slowdowns or interruptions at either location due to the impacts of the war including personnel absences as a number of our employees have been called to active military duty, or due to other resource constraints such as the inability to source materials for production. For the quarter ended September 30, 2023, net sales of products manufactured at these sites comprise approximately 3% of our consolidated net sales and 18% of the net sales attributed to our Orthodontics and Implants Solutions segment. Net assets within Israel total \$193 million as of September 30, 2023, consisting primarily of acquired technology, cash, inventory, and property, plant and equipment associated our operations in country.

The full impact of these events on economic conditions in these regions is currently unknown and could have a material adverse effect on our results of operations, cash flows or financial condition.

There have been no other significant material changes to the risk factors as previously disclosed in Part 1A, "Risk Factors" in the 2022 Company's Form 10-K as amended, for the year ended December 31, 2023.

Item 2 – Unregistered Sales of Securities and Use of Proceeds

During the three months ended September 30, 2023 March 31, 2024, the Company had no repurchases of common shares under the stock repurchase program.

On July 28, 2021 November 7, 2023, the Board of Directors approved a an increase to the authorized share repurchase program of up to \$1.0 billion. On March 3, 2023, the Company entered into an ASR Agreement with a financial institution, to repurchase \$150 million of the Company's common stock. The ASR Agreement final settlement occurred on April 28, 2023 \$1.0 billion. For further information on the ASR Agreement see Part I, Item 1, Note5, Earnings Per Common Share, in the Notes to Unaudited Interim Consolidated Financial Statements of this Form 10-Q. At September 30, 2023 March 31, 2024, the Company had authorization to repurchase \$590 million \$1.44 billion in shares of common stock remaining under the share repurchase program.

Item 5 - Other Information

Rule 10b5-1 Trading Plans

During the quarter three months ended September 30, 2023 March 31, 2024, none of the Company's directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.

Item 6 – Exhibits

Exhibit Number	Description
10.1	Form of Amended and Restated DENTSPLY SIRONA Inc. Indemnification Agreement dated as of February 27, 2024* (1)
31.1	Section 302 Certification Statement Chief Executive Officer
31.2	Section 302 Certification Statement Chief Financial Officer
32	Section 906 Certification Statements
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Extension Labels Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Management contract or compensatory plan.

(1) Incorporated by reference to exhibit included in the Company's Form 10-K for the fiscal year ended December 31, 2023, File 0-16211.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

/s/ Simon D. Campion

Simon D. Campion

President and

Chief Executive Officer

November May 2, 2023 2024

Date

/s/ Glenn G. Coleman

Glenn G. Coleman

Executive Vice President and

Chief Financial Officer

November May 2, 2023 2024

Date

69 50

Exhibit 31.1

Section 302 Certifications Statement

I, Simon D. Campion, certify that:

1. I have reviewed this Form 10-Q of DENTSPLY SIRONA Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

/s/ Simon D. Campion

Simon D. Campion

President and

Chief Executive Officer

Exhibit 31.2

Section 302 Certifications Statement

I, Glenn G. Coleman, certify that:

1. I have reviewed this Form 10-Q of DENTSPLY SIRONA Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 2, 2023 May 2, 2024

/s/ Glenn G. Coleman

Glenn G. Coleman
Executive Vice President and
Chief Financial Officer

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DENTSPLY SIRONA Inc. (the "Company") on Form 10-Q for the period ended September 30, 2023 March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Simon D. Campion, President and Chief Executive Officer of the Company, and Glenn G. Coleman, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge and belief:

1. The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of the date of the Report.

/s/ Simon D. Campion

Simon D. Campion
President and
Chief Executive Officer

/s/ Glenn G. Coleman

Glenn G. Coleman
Executive Vice President and
Chief Financial Officer

November May 2, 2023 2024

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.